 
 
 
Protocol I4T-MC- JVDT(c)  
 
 
A Single -Dose Study in Healthy Participants to Characterize Ramucirumab  
Pharmacokinetics and Investigate Injection Site Reactions Following an 
Intravenous Infusion or Subcutaneous Administration of Ramucirumab 
 
 
[STUDY_ID_REMOVED]  
 
 Approval Date: 21- Oct-2020  
&21),'(17,$/ ,70&-9'7F
7LWOH3DJH
&RQILGHQWLDO,QIRUPDWLRQ
7KHLQIRUPDWLRQFRQWDLQHGLQWKLVGRFXPHQWLVFRQILGHQWLDODQG LVLQWHQGHGIRUWKHXVHRIFOLQLFDOLQYHVWLJDWRUV,WLVWKHSU RSHUW\RI(OL
/LOO\DQG&RPSDQ\RULWVVXEVLGLDULHVDQGVKRXOGQRWEHFRSLHG E\RUGLVWULEXWHGWRSHUVRQVQRWLQYROYHGLQWKHFOLQLFDOLQYHV WLJDWLRQRI
UDPXFLUXPDE/< XQOHVVVXFKSHUVRQVDUHERXQGE\DFRQILGHQWLDOLW\DJUHHPHQW ZLWK(OL/LOO\DQG&RPSDQ\RULWV
VXEVLGLDULHV
1RWHWR5HJXODWRU\$XWKRULWLHV 7KLVGRFXPHQWPD\FRQWDLQSURWHFWHGSHUVRQDOGDWDDQGRUFRPPHU FLDOO\FRQILGHQWLDOLQIRUPDWLRQ
H[HPSWIURPSXEOLFGLVFORVXUH(OL/LOO\DQG&RPSDQ\UHTXHVWVF RQVXOWDWLRQUHJDUGLQJUHOHDVHUHGDFWLRQSULRUWRDQ\SXEOLFUHO HDVH,Q
WKH8QLWHG6WDWHVWKLVGRFXPHQWLVVXEMHFWWR)UHHGRPRI,QIRU PDWLRQ$FW)2,$([HPSWLRQ DQGPD\QRWEHUHSURGXFHGRU
RWKHUZLVHGLVVHPLQDWHGZLWKRXWWKHZULWWHQDSSURYDORI(OL/LOO \DQG&RPSDQ\RULWVVXEVLGLDULHV
3URWRFRO7LWOH$6LQJOH 'RVH6WXG\LQ+HDOWK\3DUWLFLSDQWVWR & KDUDFWHUL]H5DPXFLUXPDE
3KDUPDFRNLQHWLFVDQG,QYHVWLJDWH,QMHFWLRQ6LWH5HDFWLRQV)ROORZ LQJDQ
,QWUDYHQRXV,QIXV LRQRU6XEFXWDQHRXV$GPLQLVWUDWLRQ RI5DPXFLUXP DE
3URWRFRO1XPEHU ,70&-9'7
$PHQGPHQW1XPEHU F
&RPSRXQG /<
6WXG\3KDVH 3KDVH
6KRUW7LWOH 6LQJOH'RV H6WXG\LQ+HDOWK\3DUWLFLSDQWVWR&KDUDFWHUL]H5DPXF LUXPDE
3KDUPDFRNLQHWLFV DQG6DIHW\DIWHU6XEFXWDQHRXV$GPLQLVWUDWLRQLQ &RPSDULVRQWR
,QWUDYHQRXV ,QIXVLRQ
$FURQ\P  -9'7
6SRQVRU1DPH (OL/LOO\DQG&RPSDQ\
/HJDO5HJLVWHUHG$GGUHVV (OL/LOO\DQG&RPSDQ\,QGLDQDSROLV,QGLDQD86$
5HJXODWRU\$JHQF\,GHQWLILHU1XPEHUV
,1'
$SSURYDO'DWH 3URWRFRO(OHFWURQLFDOO\6L JQHGDQG $SSURYHG E\ /LOO\0D\
3URWRFRO$PHQGPHQWD (O HFWURQLFDOO\6L JQHGDQG $SSURYHG E\ /LOO\-XQH
3URWRFRO$PHQGPHQWE (OHFWURQLFDOO\6LJQHGDQG $SSURYHG E\ /LOO\-XO\
3URWRFRO$PHQGPHQWF (OHFWURQLFDOO\6L JQHGDQG $SSURYHG E\ /LOO\RQGDWHSURYLGHGEHORZ
Approval Date: 21-Oct-2020 GMT
CONFIDENTIAL I4T-MC-JVDT (c)
2Medical Monitor Name [CONTACT_9352] [CONTACT_17055] .
CONFIDENTIAL I4T-MC-JVDT (c)
3Protocol Amendment Summary of Changes Table
DOCUMENT HISTORY
Document Date
Amendment(b) 14-Jul -2020
Amendment(a) 26-Jun -2020
Original Protocol 15-May -2020
CONFIDENTIAL I4T-MC-JVDT (c)
4Amendment (c):
Overall Rationale for the Amendment:
This amendment addresses the sponsorâ€™s and investigatorâ€™s decisio n to allow doses to be reduced 
for rem aining groups ,as required .
Section # and Name [CONTACT_23688]
1.1 Synopsis Based on the safety review of Groups 1 and 2 :
ï‚·clarified that SC ramucirumab dosing will 
consist of up to 3 dose levels ,
ï‚·remove dsentinel dosing for Group 3 IV 
dosing ,
ï‚·reduced dose from 700mg IV to a maximum 
dose of 350mg IV and reduced IV infusion 
volume from 70 mL to 35 mL for Group 3,
ï‚·indicated that Group 6 will be optional and 
reduced maximum dose to 350 mg,
ï‚·indicated that subsequent dose levels may be 
reduced ,and
ï‚·indic ated that IV and SC doses will not exceed 
350mgfor remaining groups .To enhance the safety of 
the participants. The 
700mg dose was deemed 
unacceptable based on 
cases of asymptomatic 
transaminase increases, so 
the dose capped was at 
350mg.
1.[ADDRESS_842927] of 
up to 3 dose levels for subsequent dose -escalation 
groups.To enhance the safety of 
the participants based on 
safety review of Groups 1 
and 2.
4.1 Overall Design Based on the safety review of Groups 1 and 2 :
ï‚·remove dsentinel dosing for Group 3 IV 
dosing ,
ï‚·reduced dose from 700mg IV to a maximum 
350mg IVfor Group 3,
ï‚·indicated that Group 6 may be dosed at a 
maximu
m dose of 350 mg according to the 
pharmacy manual if safety results are 
acceptable and of scientific value,
ï‚·clarified that SC ramucirumab dosing will 
consist of up to 3 dose levels,
ï‚·indicated that subsequent dose levels may be 
adjusted based on safety reviews , 
ï‚·removed Group 6 data for further 
implementation of loading dose regimen , and To enhance the safety of 
the participants.
CONFIDENTIAL I4T-MC-JVDT (c)
5Section # and Name [CONTACT_23688]
ï‚·indicated that exclusion criteria will be revised
based on transaminase increases .
4.1 Overall Design Indicated that participants should follow local 
guida nce and CRU precautions to minimize the risk 
for COVID-19.To minimize the risk for 
COVID -19 infection.
4.3 Justification of 
DoseBased on the safety review of Groups 1 and 2 :
ï‚·reduced dose from 700mg IV to a maximum 
dose of 350mg IV for Group 3,
ï‚·reduced max imum dose level from 1400 mg to 
350mg for Group 6,
ï‚·indicated Gro up6 may not be needed based on 
emerging data , 
ï‚·capped maximum dose at 350 mg for all 
subsequent gro ups because of the acceptable 
safety profile , and
ï‚·added explanation that margin of safety table 
was based on originally planned doses .To enhance the safety of 
the participants.
5.2 Exclusion Criteria For Exclusion Criterion [14] :
ï‚·removed 1.[ADDRESS_842928], and
ï‚·added AST and GGT.To enhance the safety of 
the pa rticipants based on 
safety review of Groups 1 
and 2.
5.2 Exclusion Criteria For Exclusion Criterion [15] :
ï‚·removed 1.[ADDRESS_842929], and
ï‚·removed isolated bilirubin >[ADDRESS_842930] bilirubin <35%.To enhance the safety of 
the participants based on 
safety review of Groups 1 
and 2.
5.2 Exclusion Criteria For Exclusion Criterion [16] :
ï‚·removed with exception of Gilbertâ€™s syndrome 
or asymptomatic gallstones, and 
ï‚·specified that Gilbertâ€™s syndrome is not 
acceptable.To enhance the safety of 
the participants based on 
safety review of Groups 1 
and 2.
6.1 Study 
Intervention(s) 
AdministeredBased on the safety review of Groups 1 and 2 :
ï‚·reduced dose from 700mg IV to a maximum 
of 350mg IV for Group 3,
ï‚·removed 1400 m g SC dose , and
ï‚·removed reference to approximately 30 minute 
duration for SC infusion (with pump) and 
added reference to the pharmacy manual .To enhance the safety of 
the participants.
CONFIDENTIAL I4T-MC-JVDT (c)
6Section # and Name [CONTACT_23688]
8.2.3 
ElectrocardiogramsRemoved reference to Section 7 for QTc withdrawal 
criteria and any additional QTc readings.To remove a reference 
that was inadvertently 
included in the protocol.
[IP_ADDRESS] 
Pharmacokinetic 
Statistical InferenceModified the dose range investigate dfrom [ADDRESS_842931] 
not been summarized
Abbreviations: AST = aspartate aminotransferase ; COVID -19 = coronavirus disease 2019; CRU = clinical research 
unit; GGT = g amma -glutamyl transferase ; IV = intravenous; PK = pharmacokinetic; QTc =corrected QT interval ; 
SC = subcutaneous; ULN =upper limit of normal .
CONFIDENTIAL I4T-MC-JVDT (c)
7Table of Contents
1. Protocol Summary .................................................................................................... [ADDRESS_842932] ivities (SoA) ...................................................................................... 14
Pharmacokinet ic and Immunogenicit y Sampling ......................................................... 22
2. Introduction .............................................................................................................. 24
2.1. Study  Rati onale .......................................................................................................... 24
2.2. Background ................................................................................................................ 25
2.3. Benefit/Risk Assessment ............................................................................................ [ADDRESS_842933] yle Considerat ions............................................................................................. 37
Meals and Dietary  Restri ctions................................................................................... 37
Caffeine, Alcoho l, and Tobacco .................................................................................. 37
Activity...................................................................................................................... 38
5.4. Screen Failures ........................................................................................................... 38
6. Study Intervention .................................................................................................... 39
6.1. Study  Intervent ion(s) Administered ............................................................................ 39
Speci al Treatm ent Consi derat ions............................................................................... 40
6.2. Preparati on/Handling/Storage/Accountabilit y............................................................. 40
6.3. Measures to Minimize Bias: Rando mizat ion and Blinding .......................................... 41
Package and Labeling ................................................................................................ .42
6.4. Study  Intervent ion Compliance ................................................................................... 43
6.5. Concomitant Therapy ................................................................................................ .43
6.6. Dose Modi fication...................................................................................................... 43
6.7. Intervention after the End of the Study ........................................................................ 43
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .................................................................................... 44
7.1. Discontinuati on of  Study  Intervent ion........................................................................ 44
7.2. Parti cipant Discontinuati on/Wi thdrawal fro m the Study ............................................. [ADDRESS_842934] to Follow- Up...................................................................................................... 45
8. Study A ssessments and Procedures ......................................................................... 46
8.1. Efficacy Assessments ................................................................................................ .46
CONFIDENTIAL I4T-MC-JVDT (c)
88.2. Safety Assessments .................................................................................................... [ADDRESS_842935] ics................................................................................. 56
Treatment Compliance ................................................................................................ 56
9.4. Statistical Analyses ..................................................................................................... 57
Safety Analyses .......................................................................................................... 57
Pharmacokinet ic Analyses .......................................................................................... 57
Other Safet y Analyses ................................................................................................ 58
Immunogenici ty Assessments ..................................................................................... 58
Other Analyses ........................................................................................................... 59
9.5. Interim Analyses ......................................................................................................... 59
9.6. Data Monitoring Committee (DMC) ........................................................................... 59
10. Supporting Documentation and Operational Considerations ................................ 60
10.1. Appendix 1: Regulatory , Ethical , and Study  Oversight 
Consi derati ons............................................................................................................ 60
Regulatory  and Ethi cal Considerat ions........................................................................ 60
Inform ed Consent Process .......................................................................................... 60
Data Protection ........................................................................................................... 61
Disseminat ion of Clinical Study  Data ......................................................................... 61
CONFIDENTIAL I4T-MC-JVDT (c)
9
Data Qualit y Assurance .............................................................................................. 62
Source Documents ...................................................................................................... 63
Study  and Si te Start and Cl osure ................................................................................. 63
Publicat ion Policy ....................................................................................................... 64
Long -Term  Sample Retent ion..................................................................................... 64
10.2. Appendix 2: Clinical Laboratory  Tests ........................................................................ 65
Blood Sam pling Summary .......................................................................................... 67
10.3. Appendix 3: Adverse Events: Definit ions and Procedures for 
Recording, Evaluat ing, Follow -Up, and Reporting ...................................................... 68
Definit ion of AE......................................................................................................... 68
Definit ion of SAE ....................................................................................................... 69
Recording and Fo llow-Up of  AEs and/or SAEs .......................................................... 70
Reporting SAEs .......................................................................................................... 72
Sponsor Surveillance Process for Dose Escalat ion or Group 
Expansio n................................................................................................................... 72
10.4. Appendix 4: Contraceptive Guidance and Co llection of Pregn ancy  
Inform ation................................................................................................................. 74
10.5. Appendix 5: Genetics ................................................................................................ .76
10.6. Appendix 6: Pharmacokinet ic Profile Simulation (Intravenous 
versus Subcutaneous) ................................................................................................ .77
10.7. Appendix 7: Abbreviat ions......................................................................................... 80
10.8. Appendix 8: Protocol Amendment History ................................................................ .84
11. References ................................................................................................................. 88
CONFIDENTIAL I4T-MC-JVDT (c)
101. Protocol Summary
1.1. Synopsis
Protocol Title : A Single -Dose Study in Healthy Participants to Characterize Ramucirumab 
Pharmacokin etics and Investigate Injection Site Reactions Following an 
Intravenous Infusion or Subcutaneous Administration of Ramucirumab
Short Title : Single-Dose Study  in Heal thy Participants to Characteri ze Ram ucirumab 
Pharmacokinet ics and Safet y after Subcutaneous Administration in Comparison to 
Intravenous Infusio n
Rationale :
Ramucirumab (Cy ramza Â®; LY3009806) drug substance (hereafter referred to as ramucirumab) ,
administered as an intravenous (IV) infusio n, is approved forseveral cancer indicat ions. T here 
may be an opportunit yto optimize the ramucirumab pharm acokinetic ( PK)profile using a 
subcutaneous (SC) formulation.The clinical development of IV ramucirumab has been exclusively 
done in cancer patient s. The l arge clinical data with IV ramucirumab, together with the nonclinical 
toxicology data, support investigating single IV and SC doses of ramucirumab in a healt hy human 
popul ation. 
For the new ,proposed ramucirumab SCroute of administration, theimportant biopharmaceut ic 
questions (such as PK and bioavailabilit y)will be more efficient ly investigated in the healthy 
human populati on.
The proposed study  (I4T-MC-JVDT [JVDT] )will be the first -in-human study  invest igating single 
administration of IV ram ucirumab (1dose l evel) and SC ramucirumab ( up to 3dose levels) to 
establish the PK and safety  profiles in healt hy part icipan ts. Thi s wil l allow both safe dosi ng of the
new SC form ulation and provi de single -dose ram ucirumab safet y and PK profiles (both IV and 
SC) on which to build the remainder of the program.
In order to ensure safet y, the dosesplanned in the proposed studywill aim tonot exceed the 
plasma concentrations ( maximum drug concentration [C max] and area under the concentration 
versus time curve [ AUC ]) tested in previous studies with ramucirumab IV. Furthermore ,it is 
understood that SC administration of a monocl onal antibody  leads to l ower pl asma levels (C max
and AUC) than the same dose administered IV.Comprehensive details onthe Study JVDT de sign 
is presented in the overall study  design secti on.
CONFIDENTIAL I4T-MC-JVDT (c)
11Objectives and Endpoint s
Object ives Endpoints
Primary
ï‚·Evaluate ramucirumab safet y 
following a single dose in healt hy 
participants
ï‚·Assess inject ion site reactions 
(ISRs) fo llowing SC 
administration of ramucirumab
using ISR quest ionnaire
ï‚·Assess ramucirumab PK 
following a single dose of IV or 
SC administration ï‚·Incidence of adverse events (AEs), 
treatm ent-emergent adverse events 
(TEAEs), and serious adverse events 
(SAEs) after IV administration andSC 
administration in healt hy participant s
ï‚·Characterization and measurement of 
incidence and severit y of ISRs (including 
inject ion site pain ) using data collected 
from the ISR questi onnaire
ï‚·PK parameters: 
oIV: area under the concentration versus 
time curve (AUC) from zero to infinit y 
(AUC [0-âˆž]), maximum drug 
concentration (C max), and time o f 
maximum concentration (tmax)
oSC: AUC (0-âˆž), Cmax, tmaxafter SC 
administration 
Overall Design
Study  JVDT will be the first -in-human study  investi gating single SCor IVadministration of 
ramucirumab in healthy participants . The study  will be at a single site .The study  will be 
participant -and invest igator -blinded, rando mized, and placebo -controlled 
(7ramucirumab: 3placebo per group/dose level) . Placebo will be used as a comparator for both IV 
and S C to allow interpretation of safet y and tol erabili ty data foll owing administrati on.The reason 
for randomizing 10 parti cipants per group i s to u ltimately ensure that at least8participants
(6ramucirumab :2placebo) in each group complete the study (that i s,complete the first 40 day s of 
study  procedures per the schedule of events ;see Section 4.4).Replacement part icipant s may be 
enrolled if needed to reach the planned number of completers .
There will be sentinel dosing in this protocol ;the initial2 partici pants will be randomized / do sed
(1ramucirumab :1 placebo) ,and subsequent ly(the next day ),the rem aining participants in the 
group will be dosed . This will be subject to a satisfactory  safet y review by  [CONTACT_3170]. 
This will occur on the first dose of SC (Group 1) .
CONFIDENTIAL I4T-MC-JVDT (c)
12Parti cipants may receive eit her a single dose of IV ramucirumab ora single dose of SC 
ramucirumab ( up to 3 increasing/escalat ing dose l evels ) to establish the PK and safet y profiles. It 
is planned that maximum 6groups will be sequent ially enrolled and th e doses envisio ned are those 
below :
ï‚·Group 1: SC ramucirumab 350 mg ([ADDRESS_842936] ion of 2 mLÃ—175 mg/mL)
ï‚·Group 2: SC ramucirumab 700 mg ([ADDRESS_842937] ions of 2 mLÃ—175 mg/mL)
ï‚·Group 3: IV ramucirumab to a m aximum  of 350 mg (60-minuteIV infusio n; maximum 
35mLÃ— 10mg/mL)
ï‚·Group 4: SC ramucirumab 350 mg ([ADDRESS_842938] ions of 2 mLÃ—87.5 m g/mL)
ï‚·Group 5: SC ramucirumab 350 mg ([ADDRESS_842939] ions of 1 mLÃ—175 mg/mL)
ï‚·Optional Group 6: SC ramucirumab (maximum planned dose level, 350 mg,given as slow 
SC infusio n). 
Group s4 and [ADDRESS_842940] ion ([ADDRESS_842941] ions of 1 mLÃ—175 mg/mL) and different concentration of the drug 
product (2 injections of 2 mLÃ—87.5 m g/mL) com pared to the first group dosed at 350 mg 
(1inject ion of 2 mLÃ—175 m g/mL). Data from  these groups will provide insigh t about the effect of 
inject ion volumes and ramucirumab concentrati on on the PK and tolerabili ty of SC ram ucirumab.
The init ial dose planned for Groups3 and [ADDRESS_842942] igator (see Section 4.3for rati onale).
More preci sely, f ollowing the emerging data fro m Group s1 and 2,the study  doses aremodified 
downwards . Thi s is pending the full safet y review of all data fro m Groups 1 and 2. The IV dose
(
Group 3) will not exceed 350 mg , and t he subsequent SCdoses will be capped at 350 mg
(Groups 4 through 6).In Section4.3( Justificat ionfor Dose ), Groups1 and 2 safet y data j ustifying 
that change are presented in more detail.
Disclosure Statement : This is a PKand safet y study  to test both the marketed ramucirumab IV 
formulation and a novel ramucirumab SCformulationin healt hy participants with the obj ective of 
comparing PK exposure and safet y following both route sof administrati on. 
Number of Participant s:
Approximately 60participants willbe enrolled and randomly assigned to study  intervent ionto 
obtain at least 48evaluable participants for an estimated total of at least 8 evaluable participants 
per intervent ion group (Section 9.2).
Intervention Groups and Duration :
Participants will be screened wit hin 28 days prior to Day  1 of dosing for each group. Within each 
group ,participants will be rando mized to receive a single dose of IV or SC ramucirumab or 
placebo ( 7ramucirumab: 3placebo per group). 
CONFIDENTIAL I4T-MC-JVDT (c)
13The dosing group sor treatm ent intervent ion are as stated in the study  design:
ï‚·Group 1: SC ramucirumab 350 mg ([ADDRESS_842943] ion of2mLÃ—175 mg/mL)
ï‚·Group 2: SC ramucirumab 700 mg ([ADDRESS_842944] ions of 2 mLÃ—175 mg/mL)
ï‚·Group 3: IV ramucirumab to a m aximum  of 350mg (60-minuteIV infusio n; maximum 
35mLÃ— 10 m g/mL )
ï‚·Group 4: SC ramucirumab 350 mg ([ADDRESS_842945] ions of 2 mLÃ—87.5 m g/mL)
ï‚·Group 5: SC ramucirumab 350 mg ([ADDRESS_842946] ions of 1 mLÃ—175 mg/mL)
ï‚·Optional Group 6: SC ramucirumab (maximum planned dose level, 350 mg,given as slow 
SC infusio n). 
The 3dosing groups will be sequent ially enrolled/dosed after at minimum 2 -week safet y 
observat ionfrom the previous group has been reviewed . However, Groups4 and 5 receiving the 
same SC ram ucirumab dose as Group 1 m ay be dosed simultaneously to Group 3.
Parti cipants will be admitted to the clinical research unit ( CRU )as part of an inpatient visit on 
Day -1. Parti cipants will be discharged from the CRU on Day  8at the end of the inpat ient visit 
after all study  assessments for that visit have been completed and in agreement with the 
investigator. Participants will return thereafter to the CRU for clinical assessments and blood 
samples on an outpatient basis (according to the protocol S chedule of Activit ies) until the final 
follow-up visit approximately [ADDRESS_842947] ion.
Data Monitoring Committee : No
1.2. Schema
Abbreviations: IV = intravenous; LY = ramucirumab (LY3009806); Pbo = placebo; PK=pharmacokinetic(s); SC=subcutaneous.

CONFIDENTIAL I4T-MC-JVDT (c)
141.3. Schedule of Activities (SoA)
Procedures/
AssessmentsScreening Baseline Inpatient Outpatient EoT F/U Comments
Dosing ED
Visit 1 2 3 4 5 6 [ZIP_CODE]
Study Day -28 to -2 -1 1 2 3 
Â±14 
Â±15 
Â±16 
Â±17 
Â±18 
Â±112 
Â±115 
Â±122
Â±131
Â±240
Â±250
Â±390
Â±3
Week -4 1 1 1111 1 2 2 3 4 [ZIP_CODE]
Informed consent X
Review/confirm I/E criteria X P
Complete medical history X
Review preexisting 
conditio ns/AEsX X P X X X X X X X X X X X X X XAE g rading will be via C TCAE
version 5.0.
Concomitant medications X X P X X X X X X X X X X X X X X
Substance use 
(alcohol, tobacco)X XBreath ethanol testing will be 
performed.
Physical examination
X X X X XComplete physical examination will be 
performed at screening; brief physical 
examination at other time points.
Symptom -directed physical 
examinations may be conducted at any 
time, as deemed necessary by [CONTACT_1275]. 
Weight X X P X X
Height X
CONFIDENTIAL I4T-MC-JVDT (c)
15Schedule of Activities (SoA)
Procedures/
AssessmentsScreening Baseli ne Inpatient Outpatient EoT F/U Comments
Dosing ED
Visit 1 2 3 4 5 6 [ZIP_CODE]
Study Day -28 to -2 -1 1 2 3 
Â±14 
Â±15 
Â±16 
Â±17 
Â±18 
Â±112 
Â±115 
Â±122
Â±131
Â±240
Â±250
Â±390
Â±3
Week -4 1 1 1111 1 2 2 3 4 [ZIP_CODE]
Vital signs 
(PR, BP)X X X X X X X X X X X X X X X X XSee Section 8.2.[ADDRESS_842948] 5 minutes in the supi[INVESTIGATOR_2547] 
(except body temperature). Blood 
pressure and heart rate will be 
collected in triplicate.
On day s with concurrent ECGs, vital 
signs, and/or PK sampling, these 
measurements should occur at 
approximately the same time. ECGs 
and vital sign measurements should 
occur prior to blood draw. 
Vital sign measurements will be 
obtained:
ï‚·Day 1 at predose (prio r to IV or 
SC dose, but within 90 minutes 
prior to predose blood draw)
ï‚·End of infusion (IV group only)
ï‚·6hours after end of infusion (IV 
group o nly)
ï‚·Day 2 (24 hours postdose for IV 
and SC groups)
ï‚·Any time for other specified visits 
(prior to blood dr aws at same 
visit).
CONFIDENTIAL I4T-MC-JVDT (c)
16Schedule of Activities (SoA)
Procedures/
AssessmentsScreening Baseli ne Inpatient Outpatient EoT F/U Comments
Dosing ED
Visit 1 2 3 4 5 6 [ZIP_CODE]
Study Day -28 to -2 -1 1 2 3 
Â±14 
Â±15 
Â±16 
Â±17 
Â±18 
Â±112 
Â±115 
Â±122
Â±131
Â±240
Â±250
Â±390
Â±[ADDRESS_842949] be 
supi[INVESTIGATOR_17044] 5 to 
10minutes before ECG collection and 
remain supi[INVESTIGATOR_105305]. Times are referenced to the 
end of dosing. 
ECGs will be obtained:
ï‚·Day 1 at predose (prio r to IV or 
SC dose, but within 90 minutes 
prior to predose blood draw)
ï‚·End of infusion (IV group only)
ï‚·6hours after end of infusion (IV 
group o nly)
ï‚·Day 2 (24 hours postdose for IV 
and SC groups)
ï‚·Any time for other specified visits 
(prior to blood draws at same visit)
Chest x- ray
(posterior -anterio r view)XInvestigator -designated/local.
Performed at screening unless 
performed within the past 6 months, 
and x- ray/reports are available.
QuantiFERONÂ® -TB
Gold test or TSTXInvestigator -designated/local.
Follow -up TST will occur 2 to 3 days 
after screening.
CONFIDENTIAL I4T-MC-JVDT (c)
17Schedule of Activities (SoA)
Procedures/
AssessmentsScreening Baseli ne Inpatient Outpatient EoT F/U Comments
Dosing ED
Visit 1 2 3 4 5 6 [ZIP_CODE]
Study Day -28 to -2 -1 1 2 3 
Â±14 
Â±15 
Â±16 
Â±17 
Â±18 
Â±112 
Â±115 
Â±122
Â±131
Â±240
Â±250
Â±390
Â±3
Week -4 1 1 1111 1 2 2 3 4 [ZIP_CODE]
Admission to CRU X
Discharge from CRU XFollowing completion of Day 8
assessments.
Ramucirumab 
administration
(IVorSC)X
HIV/Hepatitis B (surface 
antigen and core 
antibody)/Hepatitis CX
Serum immunoglobulins
(IgG, IgM, IgA)X X X X XInvestigator -designated/local.
Urinary  drug screen X X
FSH XFor women not of childbearing 
potential, FSH will be drawn to confirm 
status as defined in Inclusion Criterion 
[7b] and to be exempt for pregnancy 
tests.
Pregnancy test X X X XInvestigator -designated/local.
Serum pregnancy test will be conducted 
at screening only. Urine pregnancy test 
will be conducted at all other time 
points. A beta-human cho rionic 
gonadotropin test may be performed to 
confirm a result that is positive or in the 
postmenopausal range .
CONFIDENTIAL I4T-MC-JVDT (c)
18Schedule of Activities (SoA)
Procedures/
AssessmentsScreening Baseli ne Inpatient Outpatient EoT F/U Comments
Dosing ED
Visit 1 2 3 4 5 6 [ZIP_CODE]
Study Day -28 to -2 -1 1 2 3 
Â±14 
Â±15 
Â±16 
Â±17 
Â±18 
Â±112 
Â±115 
Â±122
Â±131
Â±240
Â±250
Â±390
Â±3
Week -4 1 1 1111 1 2 2 3 4 [ZIP_CODE]
Clinical chemistry X X X X X X X X X X XInvestigator -designated/local
HematologyX X X X X X X X X X XInvestigator -designated/local
Thyroid-stimulating 
hormone (including free 
T4)X X XInvestigator -designated/local.
Coagulation XInvestigator -designated/local. Perform 
as clinically indicated.
Urinaly sis
X X X X X X X X XInvestigator -designated/local
Pharmacogenetics 
P
CONFIDENTIAL I4T-MC-JVDT (c)
19Schedule of Activities (SoA)
Procedures/
AssessmentsScreening Baseli ne Inpatient Outpatient EoT F/U Comments
Dosing ED
Visit 1 2 3 4 5 6 [ZIP_CODE]
Study Day -28 to -2 -1 1 2 3 
Â±14 
Â±15 
Â±16 
Â±17 
Â±18 
Â±112 
Â±115 
Â±122
Â±131
Â±240
Â±250
Â±390
Â±3
Week -4 1 1 1111 1 2 2 3 4 [ZIP_CODE]
PK sample X X X X X X X X X X X X X X XSee PK and immunogenicity sampling 
table (Section 1.3.1) for details.
In the event of drug hypersensitivity 
reactions (imme diate or 
nonimmediate), up to 3 additional 
samples will be collected for PK at the 
following time points: 
ï‚·as close to the onset of the reaction 
event as possible
ï‚·at the resolution of the event
ï‚·approximately 90 days following 
the event
If more than 1 laboratory blood draw is 
scheduled at the same time, blood 
draws should be obtained in the 
following order:
ï‚·safety laboratory te sts
ï‚·PK samples
ï‚·immunogenicity samples
CONFIDENTIAL I4T-MC-JVDT (c)
20Schedule of Activities (SoA)
Procedures/
AssessmentsScreening Baseli ne Inpatient Outpatient EoT F/U Comments
Dosing ED
Visit 1 2 3 4 5 6 [ZIP_CODE]
Study Day -28 to -2 -1 1 2 3 
Â±14 
Â±15 
Â±16 
Â±17 
Â±18 
Â±112 
Â±115 
Â±122
Â±131
Â±240
Â±250
Â±390
Â±3
Week -4 1 1 1111 1 2 2 3 4 [ZIP_CODE]
Immunogenicity P X X XSee PK and immunogenicity sampling 
table (Section 1.3.1) for details.
In the event of drug hypersensitivity 
reactions (immediate or 
nonimmediate), up to 3 additional 
samples will be collected for 
immunogenicity at the following time 
points: 
ï‚·as close to the onset of the reaction 
event as possible
ï‚·at the resolution of the event
ï‚·approximately 90 days following 
the event
CONFIDENTIAL I4T-MC-JVDT (c)
21Schedule of Activities (SoA)
Procedures/
AssessmentsScreening Baseli ne Inpatient Outpatient EoT F/U Comments
Dosing ED
Visit 1 2 3 4 5 6 [ZIP_CODE]
Study Day -28 to -2 -1 1 2 3 
Â±14 
Â±15 
Â±16 
Â±17 
Â±18 
Â±112 
Â±115 
Â±122
Â±131
Â±240
Â±250
Â±390
Â±3
Week -4 1 1 1111 1 2 2 3 4 [ZIP_CODE]
Injection site reaction 
assessments X (Predose; 
1 min Â± 1min, 
10 min Â± 2min, 
30 min Â± 5min, and 
240 min Â± 10min 
postdose)X
(24 hr
Â± 4 hr
postdose)X X X X X X X X X X X X XInjection site assessments will be 
performed at the indicated time points 
on each study day. The findings from 
the assessment are recorded on the ISR 
questionnaire. Injection site pain (ISP) 
assessments are part of the solicited 
and spo ntaneous ISR assessments. All 
positive responses of pain require an 
additional assessment using the Pain 
Visual Analog S cale (Pain VAS). If 
there are [ADDRESS_842950] been admi nistered. The 
exploratory tool for injection site 
assessm ent (Scarletred) will be 
performed after each time the ISR 
questionnaire is administered for each 
injection. ISR assessments will be 
performed for the SC groups only. See 
Section 8.2.5 for details. 
Abbreviations: AE = adverse event; BP = blood pressure; CRU = clinical research unit; CTCAE = Common Terminology Crite ria for Adverse Events; 
ECG =electrocardiogram ; ED = early discontinuation; EoT = end of treatment; F/U = follow -up; FSH =follicle -stimulating hormone; HIV = human 
immunodeficiency virus; I/E = inclusion/exclusion; Ig = immunoglobulin; ISP = injection site pain; ISR = injection site reaction; IV =intravenous; 
P =predose; PK =pharmacokinetic; PR = pulse rate; SC =subcutaneous; TB =tuberculosis; TST = tuberculin skin test ; VAS = visual analog scale.
CONFIDENTIAL I4T-MC-JVDT (c)
22
Pharmacokinetic and Immunogeni city Sampling
Sample # Day Collection Time Point 
Relative to 
Ramucirumab Single 
DoseLower Limit 
For Collection 
TimeUpper Limit For 
Collection TimePharmacokinetic 
Analysis 
Ramucirumab/PlaceboImmunogenicity
ADA Assessment
IV SC ADA IV SC IV and SC
11-1 hr Â± 5 mins 
(predose)-65 mins -55 mins X
1 11 hr Â± 5 mins 
(end of infusion)55 mins 65 mins X
2 1 4 hrs Â± 10 mins 3 hrs 50 mins 4 hrs 10 mins X
3 1 1 8 hrs Â± 30 mins 7.5 hrs 8.5 hrs X X
4 2 2 24 hrs Â± 1 hr 23 hrs 25 hrs X X
5 3 3 48 hrs Â± 6 hrs 42 hrs 54 hrs X X
6 4 4 72 hrs Â± 6 hrs 66 hrs 78 hrs X X
7 5 5 96 hrs Â± 6 hrs 90 hrs 112 hrs X X
8 6 6 120 hrs Â± 6 hrs 114 hrs 126 hrs X X
9 7 7 144 hrs Â± 6 hrs 138 hrs 150 hrs X X
10 8 8 168 hrs Â± 6 hrs 162 hrs 174 hrs X X
9 12 264 hrs Â± 24 hrs 240 hrs 288 hrs X
11 10 2 15 336 hrs Â± 24 hrs 312 hrs 360 hrs X X X
CONFIDENTIAL I4T-MC-JVDT (c)
23Sample # Day Collection Time Point 
Relative to 
Ramucirumab Single 
DoseLower Limit 
For Collection 
TimeUpper Limit For 
Collection TimePharmacokinetic 
Analysis 
Ramucirumab/PlaceboImmunogenicity
ADA Assessment
IV SC ADA IV SC IV and SC
11 22End of Therapy Visit
504 hrs Â± 24 hrs480 hrs 528 hrs X
12 12 3 31 30-day  Follow -up - - X X X
13 13 40 40 days Â± 2 days - - X X
14 14 50 50 days Â± 3 days - - X X
15 15 4 9090 days Â± 3 days
~ 12 weeks- - X X X
Abbreviations: ADA = antidrug antibody; IV = intravenous; SC =subcutaneous.
The actual date and exact 24 -hour clock time of sample collection should be recorded on the requisition form. Samples are requested to be taken at the spe cified 
time; however, aberrations to the specified sampling times will not be considered protocol deviations as long as the samples are taken and the actual sampling 
time is recorded. It is essential that the actual times of doses and samples are recorded accurately on the appropriate forms .
CONFIDENTIAL I4T-MC-JVDT (c)
242. Introduction
Ramucirumab is a human receptor -targeted m onocl onal antibody  (mAb) that specifically  binds 
vascular endothelial growth factor ( VEGF ) receptor 2. Ramucirumab has been marketed 
worldwide as an intravenous ( IV)formulationsince 2014 and is well -established treatm ent, as a 
single agent and/or in combinat ion with chemotherapy , for the following second -line indications:
ï‚·gastri c or gastroesophageal jun ction (GEJ) adenocarcino ma
ï‚·non-small  cell lung cancer (NSCLC)
ï‚·colorectal  cancer (CRC) , and
ï‚·hepatocellular carcino ma (HCC)
The data generated by  [CONTACT_631701]  I4T-MC-JVDT ( JVDT )will be used to recommend a 
subcutaneous ( SC)dosing regimen for ramucirumab to be used in fur ther clinical development 
with the expectation to improve pati ent outcom es by  [CONTACT_631702] (PK)profile , 
relative to IV dosing ,as fo llows:
ï‚·achieve and maintain higher trough concentrations (C trough ) with lower peak 
concentrations (C max) while producing co mparable overall exposure at steady  
state as the IV formulat ion(10 m g/kg every 2 weeks [ Q2W ]IV),
ï‚·increase the proportion of patients achieving target C trough (>50 ï­g/mL) , and
ï‚·with an ini tial loading dose, ensure C trough >50 ï­g/mL is achieved quicklyin 
therapy .
This protocol wil l study  both IV andSCramucirumab in healt hy participants to establish PK and 
safet yafter single -dose administration .
Section 2.1and Secti on 4.3provide more details about the study  rationale,and dose j ustificat ion
and margin of safet y,respect ively. 
2.1. Study Rationale
Ramucirumab present sa biphasic disposit ionPKfollowing IV administration, with adistribut ion 
apparent terminal eliminat ion half-life ( t1/2)of approximately  20 hours and eliminat ion t1/2of 
approximately  [ADDRESS_842951] 3 days postdose before reaching the 
terminal phase where the ramucirumab concentration declined more slowly. 
Hence,there m ay be an opportunit y to optimize the ramucirumab PK profile using a nSC
formulation. AnSC formulation woul d enable ramuci rumab to be absorbed over a longer period 
of time than the 60 -minute IV infusio n,leading to a more constant ramucirumab concentration 
over the dosing interval wit h a higher C trough , lower C max,and lower peak -to-trough rati o under 
SC administration co mpared to IV administration. 
The clinical development of IV ramucirumab has been exc lusively  done in cancer pati ents. 
However, for the new proposed SC route of administration, the important biopharmaceut ic 
CONFIDENTIAL I4T-MC-JVDT (c)
25questions (such as PK and bioavailabilit y) will be more efficient ly investigated in the healthy 
human population (quest ions such as PK character istics maybe answered prior to formally 
investigat ing the efficacy of SC ramucirumab). The large clinical data with IV ramucirumab ,
together with the nonclinical toxi cology data ,support investigating single IV and SC dose sof 
ramucirumab in a healt hy human populat ion. Section 2.3(Benefit/Risk Assessment) and 
Secti on4.3(Dose Justificat ion) provide details to support the clinical invest igation o f a single 
dose of ramucirumab in hea lthy participants. 
This is a single -site study  in healt hy participants who will receive a single dose ofSC or IV 
ramucirumab. The study  will be participant -and investigator -blinded, randomized, and 
placebo-controlled ( 7ramucirumab: 3placebo per group/dose l evel). Placebo will  be used as a 
comparator for both IV and SC to allow interpretatio n of safet y andtolerabili ty data foll owing 
administration. Secti on 1.2provides the study  schema. Section 4.1present sthe study  design and 
the different group/dose levels.
The study  will provide the cri tical SC ramucirumab PK area under the concentration versus time 
curve ( AUC )data to enable the determinat ion of the bioavailabilit y by [CONTACT_631703]. It will also help further clinical devel opment in terms of cho ice of 
dosing regimen and administration condit ion (in particular by [CONTACT_631704] , or changing the concentration of SC ram ucirumab sol utionon the exposure 
and/or tolerabili ty). The SC ram ucirumab dosing will consist of subsequent dose-escalat ion 
group s (up to 3dose levels predicted to be ult imate ly used f or therapeuti c intent [see Section 4.3
for dose rati onale ]) to assess both safety  and PK behavior (exposure and bio availabilit y).
2.2. Background
See Secti on 2and Section 2.1.
2.3. Benefit/Risk Assessment
More detailed informat ion about the known and expected benefits and risks and reasonably 
expected adverse events (AEs) of ramucirumab may be found in the Investi gatorâ€™s Brochure
(IB).
The safet y profile of ramucirumab given IV in adults wit h advanced cancers across a number of 
indicat ions is well established. Adverse events of speci al interest (AESIs) ident ified for 
ramucirumab m onotherapy  include infusio n-related reacti ons(IRRs) , hypertensio n, proteinuria , 
arteri al thrombo embo licevents (ATE s), bleeding/hem orrhage and gastrointestinal (GI)
perforation. Analysis of Cycle 1 data from ramucirumab m onotherapy  Phase 3 studies in pat ients 
with advanced gastri c and hepatocellular carcino ma showed the majorit y of TEAEs reported 
were reversible Grade 1 and 2 events , occurring at similar rates in both ramucirumab and placebo 
arms.The commo nly reported TEAE swere hypertensio n, fat igue, abdo minal pain, and anemia . 
In addit ion to hy perten sion,other AESIs reported were proteinuria , bleeding/ hemorrhage events ,
and IRRs . Hypertensio n, anemia ,and anaphylaxis were the events to be reported as Grade 3 
events in the ramucirumab arm . Given that t he duration of treatment in this study is a single 
dose, much shorter than the duration of treatm ent received by c ancer patients, and the trial 
popul ation is healthy ,and therefore lacking risk factors for the majority of these events
CONFIDENTIAL I4T-MC-JVDT (c)
26(excluding IRRs ),the risk to participant sof experiencing these toxicit ies isreduced. These risks 
are considered manageable in a clinical research unit (CRU) setting and are mi tigated in the 
protocol ,as the participants willbeclosely monitored following the single- dose administration. 
This will enabl eprom pt identificat ion of AEs and treatm ent as needed. Prem edicati on is also 
considered to help reduce the severit y of potenti al immediate cutaneous reactions.
The nonclinical safet y profile of IV-administered ramucirumab has been evaluated in repeat -dose 
toxicity studies of up to [ADDRESS_842952] to the maximum planned dose (see Secti on 4.3for 
details) .
More preci sely, in nonclinical repeat -dose studies, IVramucirumab was well tolerated and no 
adverse effects were observed after once -weekly (QW) administration of ramucirumab doses up 
to 40 m g/kg in a 5-week study , or after 11 weekly administrat ions of doses up to 50 mg/kg in a
39-week study in cyno molgus mo nkeys .Secti on 4.3presents the margin o f safet y of the highest 
proposed single IV and SC ramucirumab dose in Study  JVDT rel ative to the nonclinical 
no-observed -adverse -effect l evel (NOAEL )in the [ADDRESS_842953] ate were 
observed. Because these effects emerged only after a long duration of repeated exposures, they 
are not expected fo llowing a single dose in this trial.
In the single -dose study  of ramuci rumab administered SCin monkeys , doses of up to 10-mg/kg 
ramucirumab were well -tolerated wi th no clinical signs or gross evidence of inject ionsite 
reacti ons (ISRs) .Non-adverse effects consist ing of minim al fibroblast hypertrophy  at >1 mg/kg, 
and minimal macrophage infiltrate at 10 mg/kg, were observed microscopi[INVESTIGATOR_631694]; these effects are expected outcomes of introduction of foreign protein into the SCspace and 
indicate a low potential for irritation at the inject ionsite. 
Because ramucirumab is a biotherapeutic, no genotoxicit y studies have been conducted. No 
genotoxi city is expected based on the mechanism of action. No reproductive toxicit y studies 
have been conducted. Based on the mechanism o f action, fetal harm  would be expected and 
therefore in this study ,women o f childbearing potent ial (WOCBP )are excluded and male 
participants wi th partners of childbearing potential must use con tracepti on for the requi red time 
period to mi tigate thi s risk. 
There i s no antici pated therapeutic benefit for the participants in this trial. However, participants 
may benefit fro m the screening procedures (through detection of unknown healt h issues) even if 
they receive no therapeutic benefit from the trial.
CONFIDENTIAL I4T-MC-JVDT (c)
273. Objectives and Endpoint s
Object ives Endpoints
Primary
ï‚·Evaluate ramuci rumab safet y 
following a single dose in healt hy 
participants
ï‚·Assess ISRs fo llowing SC 
administration of ramucirumab using 
ISR questi onnai re 
ï‚·Assess ramucirumab PK fo llowing a 
single dose of IV or SC administration ï‚·Incidence of AEs, TEAEs, and serious 
adverse events (SAEs) after IV 
administration andSC administration 
in healthyparticipant s
ï‚·Characterization and measurement of 
incidence and s everi ty of ISRs 
(including inject ion site pain) using 
data collected fro m the ISR 
questionnaire
ï‚·PK parameters: 
oIV: area under the concentration 
versus time curve (AUC )from zero 
to infinit y (AUC[0-âˆž]), maximum  
drug concentration (C max), time of 
maximum concentrati on(tmax)
oSC: AUC (0-âˆž), Cmax, tmaxafter SC 
administration
CONFIDENTIAL I4T-MC-JVDT (c)
28Exploratory
ï‚·Immunogenicit y
ï‚·Assess ISRs fo llowing SC 
administration of ramucirumab using 
Scarl etred toolï‚·The frequency and percentage of 
participants with preexist ing antidrug 
antibodies (ADA ) and wi th 
treatm ent-emergent antidrug ant ibody  
positive (TE ADA+) to ramucirumab
will be tabulated and any  difference 
after IV administration versus SC
administration
ï‚·For the TE ADA+ participant s,the 
distribut ion of maximum t iterswill be 
described. The frequency o f 
neutralizing ant ibodies will also be 
tabul ated in TE ADA+ participants
ï‚·The rel ationship between the presence 
of antibodies and the PK parameters ,
including safet y,to ramuci rumab after 
IV versus SC administration
ï‚·Characterization and measurement of 
incidence and severit y of ISRs using 
data coll ected fro m the exploratory  
tool
CONFIDENTIAL I4T-MC-JVDT (c)
294. Study Design
4.1. Overall Design
This is a single -site study  in healt hy participants who will receive a single dose of SC or IV 
ramucirumab . The study  will be participant -and investigator -blinded, randomized, and 
placebo -controlled ( 7ramucirumab: 3placebo per group/dose l evel). Placebo will  be used as a 
comparator for both IV and SC to allow interpretatio n of safet y and tol erabili ty data foll owing 
administration.
There will be sentinel dosing in this protocol ;the initial2 partici pants will be randomized/ dosed
(1 ram ucirumab :1 placebo) , and subsequent ly (the next day )
,the rem aining participants in the 
group will be dosed. This will be subject to a satisfactory  safet y review by  [CONTACT_3170]. This 
will occur on the first dose of SC (Group 1) .
InSecti on 4.2, addi tional rationaleis presented for the select ion of healt hyparticipants for this 
investigat ion.
Parti cipants will be screened wit hin [ADDRESS_842954] acebo (7 ramucirumab :3placebo per group).
There will be at least a [ADDRESS_842955] ion 
groups (Groups 1 and 2), and between the SC and IV groups (Group s2 and 3) while loca l 
laboratory  data i s reviewed by [CONTACT_317238]. If the safet y review is acceptable, 
Groups 4 and 5 may be dosed simultaneously to Group 3, as no dose escalat ion is occurring in 
those groups. Group 6 maybe dosed with an infusion pump once the sponsor has reviewed both 
the safet y and PK data (Groups 1 through 3) if the safety resul ts are acceptable and if there is 
scientific value for invest igating an addit ional group. The dose for Group 6 will be determined
(maximum dose 350 mg). The p lan for periodic reviews is presented Section 9.5.
The dose levels are provi ded below and may  be adjusted based on safet y reviews for preceding 
groups .
The parti cipants receiving ramucirumab in each group will be administered the following dose 
level (up to 3dose levels predicted to be ult imately used for therapeutic intent [see Section 4.3
for dose rati onale ]): 
ï‚·Group [ADDRESS_842956] a ramucirumab 350-mg SC dose
oadministered at a concentration of 175 mg/mL as 1 Ã—
2-mL inject ion.
ï‚·Group [ADDRESS_842957] ered at a concentration of 175 mg/mL as 2 Ã—
2-mL inject ions.
CONFIDENTIAL I4T-MC-JVDT (c)
30ï‚·Group [ADDRESS_842958] a ramucirumab IV dose(maximum of 350mg)
oadministered as a 60-minute infusion (maximum 35mLÃ— 10mg/mL).  
oAnalysis of safet y and PK data from Groups 1 to 3 will allow init iation 
of Group 6.
ï‚·Group [ADDRESS_842959] a ramucirumab 350-mg SC dose 
oadministered at a concentration of 87.5 mg/mL as 2 Ã—
2-mL inject ions
oThe purpose is to invest igate the effect of a different d rug product 
concentration on PK and safety and Group 1 will be the refer ence 
comparison group .
ï‚·Group [ADDRESS_842960] a ramucirumab 350-mg SC dose
oadministered at a concentration of 175 mg/mL as 2 Ã—
1-mL inject ions
oThe purpose is to invest igate the effect of a different volume 
administered at the inject ion site on PK and safet y and Group 1 will be 
the reference co mpar ison group .
ï‚·Optional Group 6 may testSCramucirumab dose, maximum 350mg,to 
further understand SC ram ucirumab PK and safety in healthy 
participants
oadministered at a concentration of 175 mg/mL administered via an 
infus ion pum p according to the pharmacy manual .
The SC inject ion site will be the abdo men. See Secti on 6.1for details.
Following the safet y review of Groups [ADDRESS_842961] also 
lead to a change in the exclusion criteria to further enhance safet y of the parti cipants. In view of 
thesefinding s, subsequent doses will be capped at 350 mg. Lo wer doses may also be studied . 
These decisio ns will be based on emerging data (seeSection 4.3for further details ).
Inject ion site pain (ISP) and ISRs will be monitored in each group, and a comparison of scorings 
will be used. The severit y of ISP and ISRs reported across all participants will be evaluated. The 
data from  Group [ADDRESS_842962] igator. Participants may be required to remain in the 
CRU l onger than Day  8, at the investigatorâ€™s discretion. Participants will be required to return to 
the CRU for clinical assessments and blood samples on an outpati ent basis (according to the 
protocol  Schedule of Activities) until the final fo llow-up visit approximately [ADDRESS_842963] ion 9.2.
Parti cipants should fo llow local guidance and CRU precautions to minimize risk for coronavirus 
disease 2019 
(COVID -19) infect ion .
CONFIDENTIAL I4T-MC-JVDT (c)
314.2. Scientific Rationale for Study Design
The healthy populat ion was selected to participate in this study  because it is the m ost optimal  
setting to gather intensive PK inform ation over a n extended period of time. This PK data are 
needed to answer the scient ific object ives o f the study ,which are to assess the bioavailabilit y of 
ramucirumab foll owing SC adminis tration.Furtherm ore, conducting the study  in healthy 
participants mit igates the potential confounding effects of disease state and concomitant 
medicat ions in patients on the primary  objective (PK and safet y) of the study . It isvery difficul t 
to achieve the study object ive in a cancer pat ient populat ion. Accurate estimat ion of AUC is 
critical for robust estimat ion of bio availabilit y. Consequent ly, ramucirumab PK sampling over at 
least 12weeks is needed to achieve that goal because of the long terminal half -life o f 
ramucirumab. 
Ramucirumab IV administrati on is important in th isstudy to accurately estimate the 
bioavailabilit y,because it is not known whether ramucirumab clearance (hence exposure) is 
similar in healt hy participants and cancer patient s.  
Ramucirumab has not been studied in healt hy human participants . However, the large clinical 
safet ydatabase of IV ram ucirumab in cancer pati ents and the preclinical stud ieswith 
ramucirumab administered IV and SCsupport investigat ing single IV and SC ram ucirumab 
dosesin healt hy participant s(see m argin o f safet y in Secti on 4.3).
Placebo will be used as a co mparator to allow optimal  interpretati on of safet y and tol erabilit y 
data following ramucirumab administrati on.
The dose justificat ion is provided in Sect ion 4.3.
The rationale for sam ple size is provided in Section 9.2.
4.3. Justification for Dose
The overall principle for the cho ice of SC ramucirumab dose l evels to be tested in this 
single- ascending dose study  in healt hy participants is:
ï‚·To support appropriate dose selection in subsequent stud iesin cancer patient swith 
multiple repeated SCramucirumab administration
ï‚·To support subsequent safe administration , in cancer patient s, of ramucirumab SC 
dosing regimen leading to
oHigher C trough (target 50 Âµg/mL) and l ower C maxfor ramucirumab compared to 
IV ram ucirumab 10 mg/kg Q2W 
oSimilar steady -state AUC as achieved fo llowing IV ramucirumab 10 m g/kg Q2W .
Simulations of PK profiles fo llowing SC dosing were performed, taking into account different 
constrain ts (for example ,maximum possible drug product concentration and maximum possible 
injectable vo lume and do se frequency) , and the m ost conservative (worse -case scenario) 
assumpt ions for bioavailabilit y and rate of absorption (0.6 bioavailabilit ywith coefficient of 
variat ion [CV] 20% and rate of absorption of 0.3/day) .Those assumpt ions are based on literature 
report about mAb PKfollowing SC administration which indicate that 60% bioavailabilit yis in 
the lower end of reported bioavailabilit y (Viola et al . 2018 ). The 20% CVon bi oavailabilit y lead 
CONFIDENTIAL I4T-MC-JVDT (c)
32to a bioavailabilit yof 0.6 (0.44 -0.79), mean (90% populat ion predict ion interval ) ,used in th ese
simulat ions. 
All of the outcom e
sfrom those simulat ions, graphs ,and tables are presented in Appendix 6
(Section10.6). 
To prepare for future investigation of the above -ment ioned ramucirumab SC dosing regimen in 
cancer patients, the proposed study  (Study  JVDT) in healt hy part icipants will investigate single 
doses of SC ramucirumab 350and700mg(with a maximum o f 2mL per inject ion site and a 
maximum o f [ADDRESS_842964] ion sites per dose administration). The starting 350-mg SC ramucirumab 
dose i s half the highest approved therapeutic dose (10 m g/kg Q2W IV). To prepare for the need 
of a loading dose in cancer patients, a ramucirumab dose of 350 mg adminis tered SC (as a sl ow 
SC infusio nwith a pum p) mayalso be invest igated in Study JVDT.
The top planned SC ramucirumab dose in Group 6 was init ially planned as a maximum dose 
level of 1400 mgin a previ ous protocol versi on. Since then, Groups1 and 2 (350 mg and 700 mg 
SC) have been enro lledand received study  treatm ent,and 2-week postdose safet y data from  
those group s were reviewed . 
Consequently, after thesafet y review , the maximum dose is to be 
capped at 350mg as this dose was associated with an acceptable safety  profile . This edict applies 
to all subsequent groups .
The emerging data suggests Group 6may not be needed given the pl anned co llection of 
inform ation at the 35 0mgSC dose (
Groups 1, 4, and 5).
In addit ion to those SC ramucirumab dose levels, a single dose of up to 350 -mg ramucirumab 
administered IV (via 60-m inute infusio n) is pl anned to enable determination o f the abso lute 
bioavailabilit yfollowing SC administration . 
The init ial ramucirumab SC doses will be determined fro m the safet y data fro m previous clinical 
experience wit h IV ramucirumab, as it is understood that the IV administration leads to higher 
plasma l evels and it is expected that tolerabilit y will be better with the SC administration.
In summary , 
ramucirumab dose levels that are proposed for Study  JVDT are :
ï‚·ramucirumab IV,originally 700 m g dose l evel and subsequent ly modified to 350 mg
IV fo llowing safet y review of Groups 1 and 2
ï‚·ramucirumab 350 m g SC
ï‚·ramucirumab 700 m g SC
The t able below present sthe margin of safet y (based on C maxor AUC) relat ive to the toxico logy 
monkey study . Thetable uses the original lyplanned maximum ramucirumab dose IV and SC ,in 
the absence of any  ramucirumab data in healthy participants andbased on the assumption that 
ramucirumab IV PK properti es are similarin healthy participants and in pat ientsand the 
assumpt ion for bioavailab ilityfollowing SC as stated above .
CONFIDENTIAL I4T-MC-JVDT (c)
33Predicted Margin of Safety at Maximum Dose in Study JVDT
StudyDose (mg/kg) 
and Route of 
Administration Cmax (Âµg/mL)Margin of 
SafetyAUC 0-168 
(mg.h/mL)Margin of 
Safety
SNBL 023.04 
(5-week monkey) 40 (IV) a
NOAEL1460 - 189 -
JVDT (SAD in 
healthy  participant s)10 (IV) b 211 7X 18.6 10X
20 (SC) c 139 11X 15.3 12X
Abbreviations: AUC 0-168 = area under the curve during the dosing interval; C max= maximum observed 
concentration; IV = intravenous; PK = pharmacokinetics; popPK = pop ulation pharmacokinetics; SAD =single 
ascending dose; SC = subcutaneous.
a40 mg/kg was the no-adverse -effect level in this study .
b700 mg is equivalent to 10 mg/kg in a 70-kg human. E xposure values from RELAY pop PK model report the 
mean ,as the toxicology data report the mean ,which is consistent with the median values reported in Appendix 6.
c1400 mg is equivalent to 20 mg/kg in a 70-kg human. The human PK model simulation of SC regimen indicates 
a mean C max of 139 Âµg/mL and mean AUC over the first week AUC 0-168 of 15.3 mg.h/mL following a 
ramucirumab 1400- mg SC administration. Appendix 6 reports median value (very close to these mean values ).
A NOAEL of 40 mg/kg was established in a 5 -week repeat dose study  in monkey . At this dose, 
Cmaxand AUC values are 11-fold and 12-foldhigher than the anticipated sy stemic exposure 
following a single SC dose of 1400 mg in Study  JVDT. At this dose, C maxand AUC values are 
7-fold and 10-foldhigher than the anticipated sy stemic exposure fo llowing a single IVdose of 
700 m g in Study  JVDT. 
Therefor e, nonclinical data provides support for the safet y of the IV and SC dose of 
ramucirumab to be investi gated i n norm al, healt hy human participants (Secti on10.6)
.
4.4. End of Study Definition
A participant is considered to have co mpleted the study  if he/she has co mpleted the first 40 days 
of study  procedure sas per the schedule of event s. If a participant does not complete the 40 days 
procedure, he /she m aybe replaced. 
The end o f the study  is defined as the date of the last vi sit of the l ast parti cipant in the study  or 
last scheduled procedure shown in the Schedule of Act ivities (SoA)for the last pa rticipant i n the 
trial globally.
CONFIDENTIAL I4T-MC-JVDT (c)
345. Study Population
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, is not permitted.
5.1. Inclusion Criteria
Parti cipants are eligible to be include d in the study only if all o f the following criteria apply:
Age
1.Parti cipant m ust be between the ages of 18and 60 years o f age,inclusive, at the time of 
signing the informed consent .
Type of Participant and Disease Characteristics
2. P articipants who are overtly healt hy as determined by  [CONTACT_17059] , physical examinat ion, vitalsign measurements , including 
electrocardi ogram  (ECG ), and laboratory  tests
3. H ave clinical laboratory  test resul ts wi thin norm al reference range for the populat ion or 
investigat ive site, or results with acceptable deviat ions that are judged to be not clinically 
significant by  [CONTACT_3170] ; have a urinary protein value <2+ on di pstick urinalysis
4.
Have venous access sufficient to a llow for blood s ampling and/or administration of study  
intervent ionfor IV administration as per the protocol
5. A re reliable and willing to make themselves available for the duration of the study  and 
are willing to fo llow study  procedures
Weight
6. B ody weight wi thin â‰¥70 kg and body  mass index (BMI) wi thin the range of 18to
32kg/m2(inclusive)
Sex
7. M ale and/or female
Contraceptive use by [CONTACT_631705].
a)Male p articipants :
ï‚·regardl ess of thei r fertility status, wi th a partner of childbearing potential, must for 
the duration of the study  or for 5 m onths fo llowing com pletion of  study  drug 
administration, whichever is longer, agree to either:
oremain abst inent, if this is their preferred and usual lifestyle (periodic 
abstinence [for example, calendar, ovulation, symptothermal, 
postovulat ion methods], declarat ion of abst inence just for the duration of a 
trial, and wi thdrawal are not acceptable methods of contraception), or
CONFIDENTIAL I4T-MC-JVDT (c)
35ouse condoms , and ensure the partner uses
ï‚§one highly effect ive (Ë‚1% failure rate) method of contraception, 
such as combinat ion oral  contraceptives, implanted contraceptives, 
or intrauterine devices, or
ï‚§one effective method of contraception, such as diaphragms wit h 
spermicide or cervical sponges with spermicide
ï‚·with pregnant partners should use condoms during intercourse for the duration of 
the study  or for 5 m onths fo llowing com pletion of  study  drug admi nistrati on, 
whichever i s longer
ï‚·who are in exclusively same -sex rel ationships (as their preferred and usual 
lifest yle) or with female partners of nonchildbearing potential are not required to 
use contraception
ï‚·shoul d refrain f rom sperm  donat ion for the dur ation of the study  or for 5 months 
following co mpletion of study  drug administration, whichever is longer.
b) Female pa rticipants :
ï‚·will not be breastfeeding or planning to breastfeed during the study
ï‚·must have a negative pregnancy test at the time of scre ening
ï‚·must be of nonchil dbearing potenti al defined as: 
oinfertile due to surgical sterilizat ion (bilateral oophorectomy, tubal 
ligation, or hy sterectomy) or having a congenital anomaly  (mullerian 
agenesis), or
opostm enopausal, as evidenced by [CONTACT_631706] l east 
12months, or
oa wom an â‰¥[ADDRESS_842965] 12months of spontaneous amenorrhea, or with a diagnosis of 
menopause prior to starting hormone replacement therapy
Informed Consent
8. C apable of giving signed informed consent as described in Appendix 1 ,which includes 
compliance wi th the requi rements and restri ctions listed in the informed consent form 
(ICF) and in this protocol
5.2. Exclusion Criteria
Parti cipants are excluded fro m the study  if any of the fo llowing cri teria apply:
Medical Conditions
1. H ave known allergies to ramucirumab, any co mponents of the formulation buffer m atrix 
or rel ated com pounds, or history  of significant atopy  
CONFIDENTIAL I4T-MC-JVDT (c)
362. Have an abnormal blood pressure (>140/90 mmHg ) and/or pulse rate as determined by 
[CONTACT_3170] 
3.
Have a history  or presence of cardio vascular, respi[INVESTIGATOR_696], hepat ic, renal, GI, endocrine, 
hematol ogical, psychiatric, or neurological disorders that could significant ly alter the 
absorpti on, m etabo lism, or eliminat ion of drugs; o rconstituting a risk when taking the 
study  interventi on; interfere wi th the evaluat ion of inject ionsite assessments, or any  other 
medical condit ion that, in the judgement of the investigator, could interfere with the 
interpretati on of  data
4. R egularly use known drugs of abuse and/or show posit ive findings on urinary 
drug/alcoho lscreening
5. H aveevidence of human immunodeficiency  virus (HIV) infection and/or posit ive HIV 
antibodies 
6. Show evidence of hepat itis C and/or posit ive hepatit is C antibody  
7. Show evidence of hepat itis B and/or posit ive hepatit is B surface ant igen 
8. H ave self -perceived dullness or loss ofsensat ion on either side of the body or the 
abdo men
9. H ave donated blood of more than [ADDRESS_842966] a history  of GI perforati on, pepti c ulcerat ion, diverti cular disease, and/or fistulae 
within [ADDRESS_842967] alanine transaminase , aspartate aminotransferase , and gamma -glutamyl  transferase 
>upper limit of normal (ULN)
15.Have bilirubin > ULN
16.Have current or chronic history  of liver disease or known hepat ic or biliary abnormalit ies
(Gilbert â€™s syndro me is not acceptable)
17.Evidence of hypothy roidism or hy perthy roidism based on clinical evaluat ion and/or an 
abnorm al thyroi d-stimulating horm one that, in the opi[INVESTIGATOR_3078] n of the invest igator, would pose 
a risk to participant safet y. Parti cipants on a stable dose of thy roid repl acement therapy  
for at least the pri or [ADDRESS_842968] ion, stroke, transient ischemic attack, cerebrovascular accident, or 
unstable angina, â‰¤6 m onths pri or to randomizat ion.
Prior/Concomitant Therapy
19.
Are current ly using aspi[INVESTIGATOR_631695] n onsteroi dalanti-inflammatory  drugs
CONFIDENTIAL I4T-MC-JVDT (c)
3720.Have part icipated, within the last 30 days, in a clinical study involving a study  
intervent ion. If the previ ous study  intervent ionhas a l ong half -life, 5 half -lives or 30 days 
(whichever is longer) should have passed.
21.Haveprevi ously com pleted or withdrawn fro m this study  or any  other study  invest igating 
ramucirumab
22.Have used or i ntend to use over -the-coun ter or prescri ption medicat ion for pain or 
inflammat ion within 7 days prior to Day  1 or during the study
Prior/Concurrent Clinical Study Experience
23.Are current ly enrolled in a clinical trial invo lving a study  intervent ion or off -label use of 
a drug or device, or are concurrent ly enro lled in any other ty pe of m edical  research 
judged not to be scient ifically or medically co mpatible with this trial
24.Have been t reatedwith biologic agents (such as mAbs, including marketed drugs) within 
3 months or 5 half -lives (whichever is longer) prior to dosing
Diagnostic Assessments
25.Have tattoos or scars over the abdomen, or other factors ( for example, rash, excessive 
folds of skin) that, in the investigator's opi[INVESTIGATOR_3078] n,woul d interfere wi th injecti on site 
assessments
Other Exclusions
26.Are deemed unsui table for inclusion in the trial in the opi[INVESTIGATOR_1649] o f the invest igator or 
sponsor
27.Have an average weekly alcoho l intake that exceeds 21 units per week (males â‰¤65years 
old) and 14 units per week (females [and males >65 year sold, if applicable]); 
1unit=12oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL o f distilled 
spi[INVESTIGATOR_17040](s)
28.Are unwilling to stop alcoho l consumpt ion during study visits/t ime in the research unit
29.Smoke more than 10 cigarettes per day  or are unable to abi de by  [CONTACT_631707]
5.3. Lifestyle Considerations
Meals and Dietary Restrictions
There are no dietary  restri ctions for this study .
Caffeine, Alcohol, and Tobacco
1.During each dosing session, participant s will abstain fro m ingesting caffeine -or 
xanthine -containing products ( for example, coffee, tea, cola drinks ,and chocolate) for 
24hours before the start of dosing unt il after collecti on of the final PKand/or 
pharmacodynamic (PD) sample.
2.During each dosing session, participant s will abstain fro m alcoho l for [ADDRESS_842969] ion of the final PKand/or PDsample.
CONFIDENTIAL I4T-MC-JVDT (c)
383.Parti cipants who use tobacco products will be instructed that use of nicotine -containing 
products (including nicotine patches) will not be permitted while they are in the CRU . 
Activity
1.Parti cipants will abstain from strenuous exercise for [ADDRESS_842970] ion for clinical laboratory  tests. Participant s may participate in light recreational 
activit ies during studies ( for example, watch ingtelevisio n, read ing).
5.4. Screen Failures
Screen failures are defined as participant s who consent to participate in the clinical study but are 
not subsequently enrolle d in the study and were not alternates.
Individuals who do not meet the criteria for participation in this study  (screen failure) maybe 
rescreened. Alternates m ay also be rescreened if out of the screening window. Rescreened 
participants shoul d be assigned a new participant number. When rescreening, some scree ning 
tests and procedures may be repeated at the investigatorâ€™s discretion. Individuals may  be 
rescreened once only . The interval between rescreenings should be at least 2weeks . With 
rescreening , the individual  must si gn a new ICF. Repeating of laboratory tests once during the 
screening period or repeating screening tests once to com ply wi th the protocol -designated 
screening period d oes not constitute rescreening.
CONFIDENTIAL I4T-MC-JVDT (c)
396. Study Intervention
Study  intervent ion is defined as an y invest igational intervent ion(s), m arketed product(s), 
placebo ,or medical device (s)intended to be administered to a study  parti cipant according to the 
study  protocol .
6.1. Study Intervention(s) Administered
Intervention 
NameRamucirumab IV 
(marketed IV 
formulation)Ramucirumab SC Placebo for SC Placebo for IV
Type Drug Drug Matching placebo Matching placebo 
Dose 
FormulationVial Vial Vial Vial
Unit Dose 
Strength(s) aExperimental Experimental Placebo Placebo
Dosage Level(s) a350mg 350or700 mg NA NA
Route of 
Administration aIV infusion
(Group 3 )SC injection (Groups 1,
2, 4, 5)
SC infusion with a 
pump (Group 6)SC injection (Groups 1,
2, 4, 5)
SC infusion with a 
pump (Group 6)IV infusion
(Group 3)
Use a Experimental Experimental Placebo Placebo
IMP and NIMP aIMP IMP NIMP NIMP
Sourcing a Provided centrally 
by [CONTACT_631708] a 
vial. Each vial will 
be labeled as 
required per country 
requirement.Study intervention will 
be provided in a vial. 
Each vial will be 
labeled as required per 
country requirement.Placebo will be 
provided in a vial. Each 
vial will be labeled as 
required per country 
requirement.Placebo will be 
provided in a vial. 
Each vial will be
labeled as required 
per country 
requirement.
Current/Former 
Names or 
Aliases aRamucirumab, 
CyramzaÂ®, 
LY3009806Ramucirumab, 
CyramzaÂ®, 
LY3009806Placebo Placebo
Abbreviations: IMP = investigational medicinal product; IV = intravenous; NA = not applicable ; 
NIMP =noninvestigational medicinal product; SC = subcutaneous.
aInformation provided in this table (dose formulation, sourcing, packaging and labeling, current/former names or 
aliases) may change throughout the study or may vary by [CONTACT_1606].
The study  intervent ionwill be administered as a slow ,IV infusio n over at l east 60minutes in 
Group 3 ; and as a nSC infusio n (with a pum p) in Group 6 per pharmacy manual ;or SC inject ion 
in Groups 1, 2, 4, and [ADDRESS_842971] resuscitatio n equipment, emergency  drugs, and 
appropriately  trained staff available during the IV or SC infusio n/SCinject ionand for at l east 
[ADDRESS_842972] completed the IV or SC infusio n/SCinject ion.
The SC inject ion site will be the abdo men. The study  intervent ion will be given in the CRU by 
[CONTACT_631709]. Study  inject ions should be given by a 
CONFIDENTIAL I4T-MC-JVDT (c)
40limited number of personnel for consistency. The site of administ ration of  each inject ion will be 
recorded ;when there is more than 1injection ,the same site will not be used but another quadrant 
will be used.
Special Treatment Considerations
[IP_ADDRESS]. Premedication for Infusions and Subcutaneous Injections
Prem edication (with IV histamine H 1antagoni sts such as diphenhydramine hydrochloride) is 
planned prior to ram ucirumab IV infusio n as specified per label for IV administration . 
Parti cipants receiving SC infusio n/injecti on will  also receive oral  premedicat ionsuch as oral 
diphenhydramine. After the IVinfusio n/or SCinfusion /inject ion, a1-hour observat ion peri od 
willbe co mpleted. Thiswillfollow the l abel instructi ons to be used wi th the IV marketed 
materi al.
Any premedicat ions given will be documented as a concomitant therapy  (see Secti on 6.5).
[IP_ADDRESS]. Management of Infusion Reactions
There i s a risk of infusio n react ionsand anaphylaxis with any bi ological  agent; therefore, all 
participants shoul d be m onitored closely . Symptoms and signs that may occur as part of an 
infusio n reaction include, but are not limited to fever, chills, nausea, headache, bronchospasm, 
hypotension, angioedema, t hroat irritation, rash, pruritus, myalgia, and dizziness. In the event 
that a significant infusio n reaction occurs, the infusion will be discont inued.
Supportive care should be emplo yed in accordance with the symptoms/signs . 
Participants shoul d 
be treated appropriately by [CONTACT_3170] . 
In the event of an IRR, every effort should be made to collect a blood sample for an 
antiramuci rumab ant ibody  determinat ion as well as for ramucirumab serum concentration as 
close to the onset of the reaction as possible, at the resol ution of  the event, and 30 days fo llowing 
the onset of the event. In the case of generalized urticaria or anaphylaxis, addit ional blood and 
urine samples should be collected as described in Appendix 2 (Clinical Laborator y Tests )
6.2. Preparation/Handling/Storage/Accountability
1.The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained during transit for all study  intervent ion received and any discrepancies are 
reported and resolved before use of the study intervent ion.
2.Only participants enro lled in the study may receive study intervent ion and only 
authori zed si te staff may  supply  or administer study  intervent ion. All study  intervent ion 
must be stored in a secure, environmentally controlled, and mo nitored (m anual  or 
autom ated) area in accordance wit h the l abeled storage condi tions wi th access limited to 
the invest igator and authorized site staff.
3.The invest igator, institution, or the head of the medical inst itution (where applicable) is 
responsible for study  interventi on accountabilit y, reconciliat ion, and record maintenance 
(that is, receipt, reconciliat ion, and final disposit ion records).
4.Further gui dance and information for the final disposit ion of unused study  interventi ons 
are provi ded in the Study  Reference Manual .
CONFIDENTIAL I4T-MC-JVDT (c)
415.Invest igators should consult the study drug information provided in the Pharmacy 
Manual or label for the specific administration info rmation (including warnings, 
precauti ons, contraindicat ions, advers e react ions).
6.3. Measures to Minimize Bias : Randomization and Blinding
Study using 
Precoded 
Randomization 
provided to siteOn Day  1,participants will be assigned a unique number (randomizat ion 
number). The randomization number encodes the participantâ€™s assig nment 
to the study , according to the randomizat ion schedule. Each participant will 
be dispensed study  intervent ion, labeled wi th his/her uni que randomizat ion 
number, throughout the study .
Parti cipants will be sequent ially enrolled to groups . Wit hin each g roup, 
participants will be rando mized to receive a single dose of IV or SC 
ramucirumab or pl acebo (7 ramucirumab: 3placebo per group).
CONFIDENTIAL I4T-MC-JVDT (c)
42Blinded study with 
unblinded site 
pharmacist who is 
dispensing drugParti cipants will be rando mly assigned in a 7:3ratio
(ramucirumab :placebo) to receive study  intervent ion.Invest igators will 
remain blinded to each participantâ€™s assigned study  intervent ion 
throughout the course of the study. In order to maintain this blind, an 
otherwi se uninvo lved third party  will be responsible for the 
reconstitution and dispensat ion of all study  intervent ion and will 
endeavor to ensure that there are no differences in time taken to dispense 
following rando mizat ion.
In the event of a Qualit y Assurance audit, the auditor(s) will be al lowed 
access to unblinded study  interventi on records at the site(s) to verify that 
rando mizat ion/dispensing has been done accurately .
Blinding will be maintained throughout the conduct of the study as 
described in the separate Blinding Plan .
Emergency  code s will be available to the invest igator. A code, which 
reveal s the study  intervent ion group for a specific study participant, may 
be opened during the study  only  if the parti cipantâ€™s well -being requires 
knowl edge of the parti cipantâ€™s treatm ent assi gnment.
If a participantâ€™s study  treatment assi gnment is unblinded, the participant 
must be discont inued fro m the study , unless the investigator obtains 
specific approval fro m anEli Lilly  and Co mpany (Lilly) clinical  
pharmaco logist (CP) or clinical research physi cian (CRP) for the study  
participant to continue in the study . During the study , emergency 
unblinding should occur only by [CONTACT_543075]â€™s 
emergency code.
In case of an emergency, the invest igator has the sole responsibilit y for 
determini ng if unblinding of a participantâ€™s treatment assignment is 
warranted for medical management of the event. The participantâ€™s safety 
must al ways be the first considerat ion in making such a determinat ion. 
Where feasible and when timing of the emergent situat ion permits, the 
investigator should attempt to contact [CONTACT_41397] a participantâ€™s treatment assignment . If the invest igator 
decides that unblinding i s warranted, i t is the responsibilit y of the 
investigator to promptly doc ument the decisio n and rationale and notify 
Lilly as soon as possible.
Package and Labeling
Ramucirumab will be provi ded as a 10-mg/mL (IV) or 175 -mg/mL (SC) preservat ive-free, sterile 
solution for injection in vials. The Pharmacy  Manual  will provi de instructi onsfor the preparati on 
of 87.5-mg/mL SC ram ucirumab . Placebo will  be provi ded as a preservat ive-free, sterile so lution 
for inject ion in vials(SC) .
Ramucirumab and pl acebo vials should be stored under refrigeration at 2Â°C to 8Â°C (36Â°F to 
46Â°F) wi th protection fro m light.
CONFIDENTIAL I4T-MC-JVDT (c)
43The study  intervent ionwill be l abeled according to the country â€™s regul atory  requi rements
6.4. Study Intervention Compliance
When the individual dose for a participant is prepared fro m a bulk supply, the preparation of the 
dose will be confirmed by a second member of the study  site staff . 
When participants are dosed at the site, they  will receive study  intervent ion directly from  the 
investigator or designee, under medical supervisio n. The date and time of each dose administered 
in the c linic will be recorded in the source documents and recorded on the case report form 
(CRF). The dose of study  intervent ion and study  parti cipant i dentificat ion will be confirmed at 
the time o f dosing by  a member of the study  site staff other than the person administering the 
study  interventi on. 
6.5. Concomitant Therapy
Parti cipants m ust abstain fro m taking prescript ion or nonprescript ion drugs (including vitamins 
and dietary  or herbal supplements) within 7 days (or 14 day s if the drug is a potential enzyme 
inducer) or 5 half -lives (whichever is longer) before the start of study intervention unt il 
completion of the fo llow-up visit, unless, in the opi[INVESTIGATOR_3078] n of the investigator and sponsor, the 
medicat ion wil l not interfere with the study .
Acetaminophen, at doses of ï‚£3grams/day , is permi tted f or use any t ime during the study .
Prem edicat ions for IRRs arepermitted for use. Other concomitant medicat ion may be considered 
on a case-by- case basis ,by [CONTACT_227553] ,if possible .
6.6. Dose Modification
If moderate or severe AEs are consistent ly observed across participants in a group or if 
unacceptable pharmaco logical effects, reasonably  attributable to ramucirumab administration in 
the opi [INVESTIGATOR_35272] ,are observed in more than [ADDRESS_842973]. Relevant 
reporting and discussio n with the Medical Monitor /Sponsor , relevant personnel, and the 
Institutional Review Boards ( IRBs)/ Independent Ethics Co mmittees ( IECs)will take place 
before resumpt ion of do sing.
If the SAE occurs in 1participant in a group , then dose escalat ion will be temporarily  halted and 
no further participants will be dosed unt il a full safety  review of the data has taken place. 
Relevant reporting and discussio n with the Medical Monito r, relevant personnel, and the 
IRB/IEC will take place before resumption of dosing.
Refer to Section 10.3.5 of Appendix 3 for addi tional informat ion about the sponsor's surveillance 
process for dose escalat ion and group expansio n.
6.7. Intervention after the End of the Study
Not applicable.
CONFIDENTIAL I4T-MC-JVDT (c)
447. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
Parti cipants discont inuing from the study  prem aturely for any  reason m ust com plete AE and 
follow-up procedures per the SoA (Section 1.3) of the protocol.
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary  for a parti cipant to perm anent ly discont inue (definit ive 
discontinuat ion) study  intervent ion.If study  intervent ion is definit ively  discontinued, the 
participant willremain in the study  for addit ional data collect ion consistent with routine safet y 
monitoring . See the SoA (Secti on 1.3)for data to be collected at the time of discont inuat ion of 
study  interventi on and fo llow-up and for any  further evaluat ions that need to be completed.
If a clinically significant finding is ident ified after enro llment, the investigator or qualified 
designee will determine if the participant can continue in the study andif any change in 
participant management is needed . Any new clinically  relevant finding shoul d be reported as 
anAE.
See the SoA (Section 1.3) for data to be collected at the time of intervent ion discont inuat ion and 
follow-up and for any  further evaluat ions that need t o be completed.
7.2. Participant Discontinuation/ Withdrawal from the Study
A participant may withdraw from  the study : 
ï‚·at any  time at his/her own request 
ï‚·at the request of his/her designee (for example, parents or legal guardian)
ï‚·at the discretion of the invest igator for safet y, behavi oral, com pliance, or 
administrative reasons
ï‚·if the participant beco mes pregnant during the study
ï‚·if enro llment in any other clinical study invo lving a study  intervent ion or enrollment 
in any other ty pe of medical research judged not to be scient ifically or medically 
compatible with this study
ï‚·if the participant , for any  reason, requi res treatm ent wi th another therapeuti c agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
Discontinuati on is expected to be uncommo n.
At the time of discont inuing from the study , if possible, an early discont inuat ion visit should be 
conducted, as shown in the SoA. See the SoA (Section 1.3) for data to be collected at the time o f 
study  discont inuat ion and fo llow-up and for any  further eval uations that need to be completed.
The parti cipant will be permanently discont inued both fro m the study  intervent ion and from the 
study  at that time.
CONFIDENTIAL I4T-MC-JVDT (c)
45If the participant withdraws consent for disclos ure of  future informat ion, the s ponsor m ay retain 
and cont inue to use any data collected before such a withdrawal  of consent .If a participant
withdraws fro m the study , he/she may  request destructi on of  any sam ples taken and not tested ,
and the invest igator must document this in the site study records .
Discontinuation of Inadvertently Enrolled Participants
If the sponsor or invest igator ident ify a participant who did not meet enrollment criteria and was 
inadvertent ly enro lled, then the participant may cont inue to follow study procedures dependent 
on the cause for the incorrect enrollment . If the investigat or and the sponsor C RP agree i t is 
medically appropriate to continue, the invest igator must obtain documented approval fro m the 
sponsor C RP to allow the inadvertently enro lled participant to continue in the study with or 
without treatm ent wi th invest igational product ( IP). The documented approval must contain the 
benefit/risk assessment and a robust clinical justification that continuing in the study will not 
jeopardi ze the parti cipantâ€™s safet y. All inadvertently  enrolled participants will co mplete s afety 
follow-up as outlined in Section 1.3(SoA), Section 8.2(Safet y Assessments), and Secti on 8.3
(Adverse Events and Serious Adverse Events) of the protocol.
7.3. Lost to Follow -Up
A parti cipant will  be considered l ost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_17066]. Si te personnel are expected to 
make diligent attempts to contact [CONTACT_10971] a scheduled visit or were 
otherwi se unable to be fo llowed up by [CONTACT_779].
Site personnel, or an independent third party , will  attem pt to collect the vital status of the 
participant within legal  and ethical boundari es for all  parti cipants rando mized, including those 
who did not get IP. Public sources may be searched for vital status informat ion. If vital status i s 
determined to be deceased
, this will be documented and the participant will not b e consi dered 
lost to fo llow-up.
Discontinuati on of  specific sites or of the study  as a who le are handled as part of Appendi x 1.
CONFIDENTIAL I4T-MC-JVDT (c)
468. Study Assessments and Procedures
ï‚·Study  procedures and their timing are summarized in the SoA (Secti on 1.3). Protocol
waiver s or exem ptions are not allowed.
ï‚·Immediate safet y concerns shoul d be discussed wit h the s ponsor immediately  upon 
occurrence or awareness to determine if the participant shoul d continue or 
discontinue study  interventi on.
ï‚·Adherence to the study  design requi rements, including those specified in the SoA, is 
essent ial and required for study  conduct.
ï‚·All screening evaluat ions must be com pleted and reviewed to confirm that potenti al 
participant s meet all eligibilit y criteria.The invest igator will maint ain a screening log 
to record details of all participant s screened and to confirm eligibilit y or record 
reasons for sc reening failure, as applicable.
ï‚·The specificat ions in this protocol for the timings of safet y and sample co llection are 
given as targets to be achieved wit hin reasonable limits. Modificat ions m ay be m ade 
to the time points based upon emerging clinical information. The scheduled time 
points m ay be subject to minor alterati ons; however, the actual time has to be 
correctly  recorded in the CRF. Failure or being late ( that is,outsi de sti pulated time 
allowances) to perform procedures or obtain samples due to legit imate clinical issues 
(for example, equipment technical problems, venous access difficult y, or participant
defaul ting or turning up late on an agreed scheduled procedure) will not be 
considered as protocol deviat ions,but the CRU will st ill be required to notify the 
sponsor in writ ing via a file note.
ï‚·Appendix 2lists the laboratory tests that will be performed for this study.
ï‚·Secti on 10.2.1 of Appendix 2 provi des a summary  of the m aximum  number and 
volume of invasive samples, for all sampling, during the study .
ï‚·Unless otherwise stated in subsect ions below, all samples collected for 
specified laboratory  tests will be destroyed within [ADDRESS_842974] results. Certain samples may  be retained for a l onger peri od, if 
necessary , to com ply with applicable l aws, regul ations, or laboratory 
certification standards.
8.1. Efficacy Assessments
Not applicable.
8.2. Safety Assessments
Planned time po ints for all safet y assessments are provided in the SoA (Section 1.3).
CONFIDENTIAL I4T-MC-JVDT (c)
47
Physical Examinations
ï‚·A co mplete physical examinat ion will include, at a minimum, assessments of the 
cardi ovascular , respi [INVESTIGATOR_696] , GI, and neurological systems. Hei ght and wei ght will also 
be measured and recorded at screening .
ï‚·A brief physical examinat ionwill include, at a min imum, assessments of the skin, 
lungs, cardiovascular system, and abdo men (liver and spleen) .
ï‚·Invest igators should pay special attention to clinical signs related to previous serious 
illnesses.
Vital Signs
ï‚·For each participant , vital sign measurements shoul d be conducted according to the 
SoA (Section 1.3) and fo llowing the study -specific recommendations included in a
Manual of Operati ons f or the study .Vital sign m easurem ents will  be recorded before 
collect ing any blood samples. 
ï‚·Blood pressu reandpulse rate should be measured after at least 5 minutes supi[INVESTIGATOR_050] , and 
taken in tri plicate .
ï‚·If orthostatic measurements are required, participants should be supi[INVESTIGATOR_1919] 
5minutes and stand for at least 3 minutes.
ï‚·If the participant feels unable to stand, supi[INVESTIGATOR_631696].
ï‚·Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of 
dizziness or posture -induced symptoms. Addit ional vital signs m ay be m easured 
during each study  period if warranted.
Electrocardiograms
ï‚·Single,12-lead ECG swill be obtained as outlined in the SoA (see Section 1.3) using 
an ECG machine that automatically  calculates the heart rate and measures pulse rate , 
QRS, QT, and corrected QTintervals (QTc). 
ï‚·For each participant, ECGs should be collected accordin g to the SoA (Section 1.3) 
and the study -specific reco mmendat ions included in the Manual o f Operati ons f or the 
study .
ï‚·Any clinically  significant findings fro m ECGs that resul t in a di agnosis ,and that 
occur after the participant receives the first dose of the study  interventi on, shoul d 
bereported to the sponsor or its desi gnee as an AE via electroni c case report 
form(eCRF )
ï‚·Electrocardiograms must be recorded before collecting any blood samples. 
Parti cipants m ust be s upi[INVESTIGATOR_17044] [ADDRESS_842975] igational site.
CONFIDENTIAL I4T-MC-JVDT (c)
48ï‚·Electrocardiograms will be interpreted by  a qualified invest igator (the physician or 
qualified designee) at the site as soon after the time of ECG collection as possible, 
and ideally  while the parti cipant i s still present, to determine whether the participant 
meets entry  criteria at the rel evant vi sit(s) and for immediate parti cipant m anagement, 
shoul d any clinically  relevant findings be identified. 
Clinical Safety Laborator y Assessments
ï‚·See Appendix [ADDRESS_842976] of clinical laboratory  tests to be performed and the 
SoA (Section 1.3)for the timing and frequency.
ï‚·The invest igator must review the laboratory report, document this review, and 
record any  clinically  relevant changes occurring during the study  in the AE 
sectionof the CRF . The laboratory  reports m ust be filed with the source 
docum ents. Clinically significant abnormal laboratory  findings are those 
which are not associated with the underlying disease, unless judged by [CONTACT_631710] â€™s condi tion.
ï‚·All laboratory  tests wi th values considered clinically significantly abnormal 
during parti cipat ion in the study ,or wi thin [ADDRESS_842977] dose of study  
intervent ion,shoul d be repeated until the values return to normal or baseline 
or are no longer considered clinically significant by [CONTACT_631711].
oIf such values do not return to normal/baseline within a peri od of  time 
judged reasonable by [CONTACT_3170], the etiology should be identified 
and the sponsor notified.
oAll protocol -requi red laboratory  assessments, as defined in Appendix [ADDRESS_842978] be conducted in accordance wit h the laboratory  manual and the SoA
(Secti on 1.3).
oIf laboratory  values fro m nonprotocol -specified laboratory  assessments ,
performed at the inst itutionâ€™s l ocal laboratory ,require a change in 
participant m anagement or are considered clinically  significant by  [CONTACT_1275] ( for example, SAE , AE,or dose m odificat ion), then the resul ts 
must be recorded in the CRF.
Injection Site Reactions
ï‚·Inject ion site assessments using the ISR q uestionnaire and an exploratory  tool
(Scarletred) will be performed at times specified in the SoA (Section 1.3). 
ï‚·Manifestati onsof a local ISRmay include ery thema, indurat ion, pain, pruri tus, and 
edem a. Inject ionsite findings will  be captured on the eCRF . 
ï‚·Inject ionsite reacti ons, whether recorded as a result of the prespecified (or solicited) 
assessment or spontaneously reported reactions, will be recorded as AEs only if they 
qualify  as severe AEs. 
CONFIDENTIAL I4T-MC-JVDT (c)
49ï‚·If a spontaneous (or unsolicited )ISR i sreported by a participant or invest igator ,the 
ISR CRF will be used to capture addit ional informati on about thi s react ion (for 
example , degree and area of ery thema) at addi tional visits until resol ution of the 
event .
ï‚·Inject ion site pain assessments are part of the solicited and spontaneous ISR 
assessments. Al l posi tive responses of pain will require an addit ional assessment 
using the Pain Visual Analog Scale ( Pain VAS) . The VAS will be performed at times 
specified in the SoA (Section 1.3). If there are [ADDRESS_842979] ion. Pain measurements will be quantified using the 100 -mm VAS pain 
score for all part icipants, regardless of whether they report ISP. The VAS is a 
well-validated tool (Williamso n and Hoggart 2005) to assess ISP; it is presented as a 
100-mm line anchored by  [CONTACT_105427], usually  â€œno painâ€ and â€œworst imaginable 
pain.â€ The parti cipant will  be asked to rate any  pain at the inject ion site on a scale of 
0to 100 mm on the line immediately (withi n 1minute) fo llowing the inject ion. 
ï‚·In addi tion, the expl oratory  tool (Scarl etred) will  be used to acqui re expl oratory  ISR 
data at each of the time points where the ISR data is being co llected by [CONTACT_631712]. Failure to take this assessment at any  of the indicated time 
points will not result in a protocol deviat ion.
Safety Monitoring
The Lilly CPor CRP/ scientist will mo nitor safet y data throughout the course of the study .This 
will include mo nitoring and recording of all AEs, including all National Cancer Institute 
Commo n Termino logy Criteria f or Adverse Events (CTCAE) v ersion 5.0 grades and SAEs.
The sp onsor will review SAEs within time frames mandated by  [CONTACT_631713]. The 
sponsor CPor CRP will periodically review the fo llowing data:
ï‚·trends in safety  data
ï‚·laboratory  analy tes including proteinuria, reduced red blood cells, and decreased 
neutrophil count 
ï‚·AEs,including monitoring of AESI s; see Section 8.3.[ADDRESS_842980].
[IP_ADDRESS]. Hypersensitivity Reactions
In the event of a suspected sy stemic allergic/hypersensit ivity react ion, addi tional safety  data 
shoul d be collected using the Infusion -related reacti on/Hypersensi tivity/Anaphylaxis fo llow-up 
form or docum ented via the eCRF.  
ï‚·Hypersensi tivity/Infusi on-Related React ions eCRFs are used to capture additional 
characterist ics of the hypersensit ivity/anaphylaxis/ inject ion-related reacti on that 
cannot be captured on the AE eCRF.
ï‚·Each symptom of the event ( for example, mucocutaneous, cardi ovascular, GI , CNS, 
other) should be assessed.
CONFIDENTIAL I4T-MC-JVDT (c)
50ï‚·If any o f the above symptoms are observed during the assessment, a single 
generalized AE record should be entered on the AE eCRF (do not include symptoms 
in AE Term /descript ion).
ï‚·Timing of the event occurrence is important. The investi gator shoul d indicate the 
timing category  that i s appropri ate.
8.3. Adverse Events and Serious Adverse Events
The definit ions of AEs and SAEs are provided in Appendix 3 (Secti on 10.3).The invest igator 
will use CTCAE v ersion 5.0 (NCI 2018) to assign AE severi ty grades.
Adverse event s will be reported by  [CONTACT_17071] (or, when appropri ate, by  a caregiver, 
surrogate, or the participant â€™s legally authori zed representative).
The invest igator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definit ion of an AE or SAE and remain responsible for fo llowing 
up AEs that are serious, considered related to the study  intervent ion or study  procedures, or that 
caused the participant to discont inue the study  (see Secti on 7).
Invest igators are responsible for monitoring the safety of participants who have entered this 
study  and f or alerting the sponsor or its desi gnee to any  event that seems unusual, even if this 
event m ay be considered an unant icipated benefit to the participa nt.
The invest igator is responsible for the appropriate medical care of participants during the study.
Time Period and Frequency for Collecting AE and SAE Information
All SAEs will be co llected fro m the signing of the ICF until participat ion in the study  has ended .
All AEs will be collected fro m the signing of the ICF until partici pation in study  has ended.
Adverse events that begin before the start of study  intervent ion, but after signing of the ICF, will 
berecorded on the AECRF.
Although all AEs after signing the ICF are recorded by  [CONTACT_41414]/electroni c data entry , 
SAE reporting to sponsor begins after the pa rticipant has signed the ICF and has received the 
study  interventi on. However, if an SAE occurs after signing the ICF, but prior to recei ving
ramucirumab , it needs to be reported ONLY if it is considered reasonably possibly related to 
study  procedures.
All SAEs will be recorded and reported to the sponsor or designee immediately ,and under no 
circumstance shoul d this exceed 24 hours, as ind icated in Appendix 3 (Secti on 10.3). The 
investigator will submit any updated SAE data to the sponsor within [ADDRESS_842981] igator learns of any SAE, including a death, at any t ime after 
a participant has been discharged from the study , and he/she considers the event to be reasonably  
related to the study  intervent ion or study  parti cipation, the invest igator must prompt ly notify  
thesponsor.
CONFIDENTIAL I4T-MC-JVDT (c)
51
Method of Detecting AEs and SAEs
The m ethod of recording, evaluat ing, and assessing causalit y of AEs and SAE sand the 
procedures for complet ing and transmitting SAE reports are provided in Appendix 3
(Secti on10.3).
Care will be taken not to introduce bias when detecting AEs and/or SAEs . Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences .
Follow -Up of AEs and SAEs
After the init ial AE/SAE report, the investigator is required to proactively fo llow each participant 
at subsequent visits/contacts. All SAEs and AE SIs(as defined in Sect ion 8.3.6 )will be followed 
until reso lution, stabilization, the event is otherwise explained, or the participant is lost to 
follow-up (as defined in Sect ion7.3). Further i nformat ion on fo llow-up procedures is provi dedin 
Appendix 3(Secti on 10.3).
Regulatory Reporting Requirements for SAEs
ï‚·Prom pt notificat ion by [CONTACT_32847] a nSAE is essent ial so that 
legal obligations and ethical responsibilit ies towards the s afety of parti cipants and the 
safet y of a study  intervent ion under clinical invest igation are met.
ï‚·The sponsor has a legal responsibilit y to notify both the l ocal regulatory  authori ty and 
other regulatory  agencies about the safet y of a study  intervent ion under clinical 
investigat ion. The sponsor will co mply with country -specific regulatory  requi rements 
relating to safet y reporting to the regulatory  authori ty, IRB/IEC , and invest igators.
ï‚·An invest igator who receives an invest igator safety report describing a nSAE or other 
specific safet y informat ion (for example, summary or list ing of SAEs) fro m the 
spons or will  review and then file it alo ng wi th the IBand will notify the IRB/IEC, if 
appropriate according to local requirements.
Pregnancy
ï‚·Details o f all pregnancies in female participants and, if indicated, female partners of 
male participants , will be co llected after the start of study  intervent ion and until at 
least [ADDRESS_842982] dose .
ï‚·If a pregnancy  is reported, the investigator should inform the sponsor within 24hours
of learning of the pregnancy and should fo llow the procedures outlined in Appendix 4
(Secti on10.4).
ï‚·Abnorm al pregnancy outcom es (for example , spontaneous abortion, fetal death, 
stillbirth, congenital ano malies, ectopi c pregnancy) are considered SAEs.
ï‚·Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an 
AE. However, to fulfill regulatory  requi rements, any  pregnancy  should be reported 
following the SAE process described in Appendix 4(Section 10.4)to collect data on 
the outcom e for both m other and fetus.
CONFIDENTIAL I4T-MC-JVDT (c)
[ADDRESS_842983] 
The sponsor CPor CRP will periodically review AESI sfor this program , which incl ude:
ï‚·bleeding/h emorrhagic events
ï‚·liver failure/liver injury
ï‚·hypertensio n
ï‚·proteinuria
ï‚·fistula
ï‚·GI perforation
ï‚·IRR (including hypersensit ivity react ions)
ï‚·wound healing complicat ions
ï‚·posterior reversible encephalopathy  syndrom e (PRES )
ï‚·ATEs
ï‚·venous thromboembolic events (VTEs)
ï‚·congest ive heart failure
When appropriate, the sponsor CPor CRP will consult with the functionally independent Global 
Patient Safet y therapeutic area physician or clinical research scient ist. 
Product Complaints
A product complaint is any written, electr onic, or oral  communicat ion that alleges deficiencies 
related to the i denti ty, quali ty, durabili ty, reliabili ty, safety, effect iveness ,or performance of a 
trial intervent ion. 
Sponsor collects product complaints on IPand drug delivery systems used in cli nical studi es in 
order to ensure the safet y of study  partici pants, m onitor quali ty, and to facili tate process and 
product improvements.
Parti cipants will be instructed to contact [CONTACT_17074] a 
complaint or probl em with the IPso that the situation can be assessed.
NOTE: AEs/SAEs that are associated with a product complaint will also fo llow the processes 
outlined in Sect ion 8.3.3 and Appendix 3(Secti on 10.3)of the protocol.
[IP_ADDRESS]. Time Period for Detecting Product Complaints
ï‚·Product complaints that result in an AEwill be detected, documented, and reported to 
the sponsor during all periods of  the study  in which the drug is used.
ï‚·If the invest igator learns of any product complaint at any time after a participant has 
been discharged from the study , and such incident is considered reasonably related to 
a drug provided for the study , the invest igator will prom ptly notify the sponsor.
CONFIDENTIAL I4T-MC-JVDT (c)
[IP_ADDRESS]. Prompt Reporting of Product Complaints to Sponsor
ï‚·Produ ct complaints will be reported to the sponsor using the Product 
Com plaint Form  within [ADDRESS_842984] igator becomes aware of the 
complaint.
ï‚·The Product Complaint Form will be sent to the sponsor by  [CONTACT_941] m ethod 
provi ded in the form. If the primary  method i s unavailable, then an alternat ive 
method provided in the form should be ut ilized.
[IP_ADDRESS]. Follow -Up of Product Complaints
ï‚·Follow-up applies to all participants, including those who discont inue study  
intervent ion.
ï‚·The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the product 
complaint.
ï‚·New or updated informat ion will be recorded on the originally co mpleted form wit h 
all changes signed and dated by [CONTACT_32848] .
8.4. Treatment of Overdose
For thi s study , any dose of ramucirumab greater than a single dose of study  intervent ionwithin a 
24-hour time period will be considered an overdose.
The s ponsor does not recommend spe cific treatm ent for an overdose .Participants shoul d receive 
appropriate supportive care measures for AESI sor other AEs, as deem ed necessary  by [CONTACT_1275].
In the event of an overdose, the invest igator/treating physician shoul d:
1.Contact [CONTACT_631714].
2.Closely  monitor the parti cipant for any  AEs/SAE sand laboratory  abnormalit ies unt il 
study  interventi oncan no l onger be detected sy stemically  (at least28days).
Decisio ns regarding dose interruptions or modifications will be made by t he invest igator in 
consultation wit h the Medical Monitor based on the clinical evaluat ion of the participant.
8.5. Pharmacokinetics
ï‚·Who le bloodsamples will be co llected for measurement of serum concentrati ons of 
ramucirumab as specified in the SoA (Section 1.3)
,Secti on1.3.1 ,and Section 10.2.1 .
ï‚·A maximum of 3samples m ay be collected at additional t ime po ints during the study 
if warranted and agreed upon between the invest igator and the sponsor . The timing of 
sampling may  be al tered during the course of the study  based on newly available data 
(for example , to obtain data closer to the time of peak plasma concentrations) to 
ensure appropriate monitoring . 
ï‚·Instructi ons for the collect ion and handling of bio logical samples will be provided by 
[CONTACT_456] . The actual date and time (24 -hour clock time) of each sampl e will  be 
recorded.
CONFIDENTIAL I4T-MC-JVDT (c)
54ï‚·Samples will  be used to evaluate the PK of ramucirum ab. 
ï‚·Genet ic analyses will not be performed on these serum samples . Parti cipant 
confident iality will be maintained . 
ï‚·Pharmacokinet icsamples will be retained for a maximum o f 1year fo llowing the last 
participant visit for the study . During this time, samples remaining after the 
bioanalyses may be used for exploratory  analyses such as metabo lism work, protein 
binding, and/or bioanalyt ical method cross -validation.
Drug concentration info rmation that mayunblind the study  will not be reported to invest igative 
sites or blinded personnel until the study has been unblinded .
Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  [CONTACT_17077] a facilit y 
designated by  [CONTACT_456].
Concentrations of ramucirumab will be assayed using a validated method. Analyses of samples 
collected from placebo treated participants are not planned.
Bioanaly tical samples collected to measure invest igational product concentrations will be 
retained for a maximum o f [ADDRESS_842985] parti cipant vi sit for the study .
8.6. Pharmacodynamics
Pharmacodynamic parameters a re not evaluated in this study .
8.7. Genetics
Genet ics are not evaluated in this study .
A blood sample for deoxyribo nucleic acid ( DNA )isolation will be co llected fro m participants . 
See Appendix 5(Secti on 10.5)for informati on regarding genetic research and Appendix 1
(Secti on 10.1.9 )fordetails about sample retention and c ustody . 
8.8. Biomarkers
Biomarkers are not eval uated in thi s study .
8.9. Immunogenicity Assessments
At the visit s and t imes specified in the SoA (Secti on 1.3) and Secti on 1.3.[ADDRESS_842986] ramucirumab . Ant ibodies 
may be further characterized for their abilit y to neutralize the activit y of the ramucirumab . To 
interpret the resul ts of immunogenicit y, a venous blood sample will be co llected at the same time 
points to determine the plasma concentrations of ramucirumab . All samples for immunogenicit y 
shoul d be taken predose when applicable and possible .
Addit ionally, blood samples for the determinat ion of ramucirumab concentration and 
antiramuci rumab ant ibodies are to be collected at the 30 -dayand 90 -dayfollow-up visit s(see 
SoA [Section 1.3]).
CONFIDENTIAL I4T-MC-JVDT (c)
55In the event of an IP- related IRR, see Section [IP_ADDRESS] .
Antiramuci rumab ant ibodies may be determined using a validated immunoassay at a laboratory  
designated by  [CONTACT_36613]. Samples may  be stored for a m aximum of 15years after 
the last participant visit for the trial ,at a facilit y selected by  [CONTACT_456] ,to enable further 
analysis of immune responses to ramucirumab. The duration allows the sponsor to respond to 
regul atory  requests rel ated to the study  drug.
Treatment -emergent antidrug ant ibodies ( TE ADAs) are defined in Sect ion 9.4.4 .
The detecti on and characterizat ion of antibodies to ramucirumab will be performed using a 
validated assay method at a laboratory  under the supervisio n of the sponsor. 
Refer to Appendix 1(Secti on 10.1.9 ) for details on Sample Retention.
8.10. Health Economics
This sect ion is not applicable for this study.
CONFIDENTIAL I4T-MC-JVDT (c)
569. Statistical Considerations
9.1. Statistical Hypotheses
Formal  statistical  hypothesis testing is not pl anned. Therefore, adjust ments for multiple testing 
do not apply. 
9.2. Sample Size Determination
Approximately 60 parti cipants will be enrolled and randomly assigned to study  intervent ion
(10per group/dose level ; 7ramucirumab :3placebo) to ob tainat least 48evaluable participants 
overall for an est imated total of at least 8 evaluable participants per intervent ion group
(6ramuciru mab and at least 2 
placebo) . The sample size is not powered on the basis o fstatistical 
hypothesis testing. A parti cipant will be considered evaluable when the parti cipant completes up 
to 40 days of study procedures. When a parti cipant does not complete up to 40days of study  
procedures , the sponsor will be consulted if the parti cipant will need to be replaced .
9.3. Populations for Analyses
The fo llowing popul ations are defined:
Population Description
Entered All participants who si gn the ICF
Enrolled/Intent -to-Treat All parti cipants assigned to treatment, regardless of whether they  
take any  doses of study  treatm ent, or if they took the correct 
treatm ent. Pa rticipants will be analyzed according to the treatment 
group to whi ch they  were assigned.
Dose Eval uable All parti cipants who com pleted treatment 
Safety All parti cipants rando mly assigned to study  intervent ion and who 
take at least [ADDRESS_842987] sufficient evaluable PK sample s.
Abbreviations: ICF = informed consent form; PK = pharmacokinetic.
Study Participant Disposition
A detailed description o f participant disposi tion will  be provi ded at the end of the study .
Study Participant Characteristics
Dem ographic and baseline characterist ics will be summarized by [CONTACT_1570].
Treatment Compliance
No analyses of treatment compliance are planned.
CONFIDENTIAL I4T-MC-JVDT (c)
579.4. Statistical Analyses
Statistical analysis o f this study  will be the responsibilit y ofthe sponsor or its desi gnee. The 
primary  analysis o f the study  will occur when there are at least8evaluable participants 
(6ramucirumab :2 placebo) per intervent ion group.
Pharmacokinet icanalyses will be conducted on data fro m all parti cipants who receive 1dose of 
IPand have evaluable PK. 
Safety analyses will be conducted in the safet y popul ation.
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate. Study  
resul ts may be pool ed wi th the resul ts of other studies for safet y and popul ation PK analysis 
purposes to avoid issues with post hoc analyses and incomplete disclosures of analyses.
Any change to the data analysis methods described in the protocol will require an amendment 
only if it changes a princi pal feature of the protocol. Any  other change to the data analysis 
methods described in the protocol, and the just ification for making th e change, will be described 
in the statist ical analysis plan ( SAP)and the clinical study  report (CSR) . Addit ional exploratory  
analyses o f the data will be conducted as deemed appropriate.
The SAP will be finalized prior to first participant, first visit ,and it will include a more technical 
and detailed descript ion of the statistical analyses described in this sect ion. This sect ion is a 
summary of the planned statist ical analyses of the most important endpoints ,including primary 
and key  secondary endpoint s.
Safety Analyses
[IP_ADDRESS]. Clinical Evaluation of Safety
All IPand protocol  procedure AEs will be listed, and if the frequency o f events allows, safet y 
data will be summarized using descript ive methodol ogy.
The incidence of AEs for each treatm ent will be presente d by [CONTACT_631715]. Adverse events reported to occur prior to study entry will be 
distinguished from those reported as new or increased in severit y during the study .Each AE will 
be classified by [CONTACT_631716] .
AllSAEs will  be reported.
[IP_ADDRESS]. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  laboratory  parameters, vi tal sign
measurement s, and ECG parameters. The parameters will be listed, and summarized using 
standard descript ive statist ics. Addit ional analysis will be performed if warranted upon review of 
the data.
Pharmacokinetic Analyses
[IP_ADDRESS]. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for ramucir umab will be calculated by  [CONTACT_105428].
CONFIDENTIAL I4T-MC-JVDT (c)
58The primary  parameters for analysis will be tmax, Cmax, and AUC of ramucirumab following IV 
and SC administration and bioavailabilit y following SC administrati on. Other noncompartmental 
param eters, such as half -life, IV cl earance , volume of distribut ion, apparent cl earance ,and 
volume of distribut ion following IV and SC ramucirumab administration may be reported.
In addi tion to noncom partmental analysis, n on-linea r mixed -effect m odelling analysis o f the 
Study  JVDT PK data will be performed. This model will enable to estimate mean and variabilit y 
(variance) of ramucirumab PK parameters fo llowing SC administrati on and to invest igate 
potenti al covariate expl aining tha t vari ability. 
[IP_ADDRESS]. Pharmacokinetic Statistical Inference
Pharmacokinet ic parameters will be evaluated to estimate ramucirumab AUC and C max dose 
proporti onali ty following SC administrati on in the dose range invest igated . Log -transform ed 
ramucirumab C maxand AUC parameters will be evaluated in a linear mixed- effects m odel with 
fixed effects for dose ( Groups1, 4, and5 who received 350 mg will be combined). The treatment 
differences will be back
-transform ed to present the ratios of geometric means and the
corresponding 90% confidence interval ( CI).
For ram ucirumab SC dosing PK parameters, the t maxwill be analyzed using a Wilcoxon 
rank-sum test. Estimates of the median difference based on the observed medians, 90% CIs, and 
p
-values fro m the Wilcoxon test w ill be calculated.
Ramucirumab bi oavailabili ty will be estimated (see Section [IP_ADDRESS] ).
Comparison of AUC and C maxbetween Group 1and Group 4will enable to assess the effect of 
changing the drug product concentration on the exposure. The log -transformed C maxand AUC 
will be the response variable, and the drug product concentration ( that is, Group 1and Group 4) 
is the explanatory  variable.  
Comparison of AUC and C maxbetween Group 1and Group 5will enable to assess the effect of 
changing the volume injected at one site of inject ion on the exposure. The log- transformed C max
and AUC will be the response variable, and the volume injected (that is,Group 1and Group 5) is 
the explanatory  variable.  
Other Safety Analyses
All safet y analyses will be made on the Safet y Popul ation.The m ost current versi on of  the 
Medical Dict ionary for Regul atory  Activities (MedDRA )at the time of analysis will be u sed 
when reporting AEs by [CONTACT_133416] ,and CTCAE v ersion 5.[ADDRESS_842988] ing antidrug ant ibodies ( ADA s)and 
with TEADA sto ramucirumab may be tabulated. 
CONFIDENTIAL I4T-MC-JVDT (c)
59Treatment -emergent ADAs are defined as those with a titer 2 -fold (1 dilution) greater than the 
minimum required dilut ion if no ADAs were detected at baseline (treatment -induced ADA) or 
those wi th a 4-fold (2 dilutions) increase in titer compared to baseline if ADAs were detected at 
baseline (treatment -boosted ADA s).
The frequency of neutralizing ant ibodies may also be tabulated in TE ADA -positive participant s, 
when available. 
The rel ationship between the presence of ant ibodies and the PK parameters ,including safet y to 
ramucirumab ,may be assessed.
Other Analyses
Other analyses may include analyses of assessments, which are not defined as endpo ints, that 
need to be prespecified and not necessarily be reported in the CSR such as, but not limited to, 
immunogenicit y, biomarkers, popul ation PK, heal th care utili zation endpoints and healt h 
techno logy assessment -related endpo ints.
9.5. Interim Analyse s 
No interim analyses are planned for this study . If an unplanned interim analysis is deemed 
necessary  for reasons other than a safet y concern, the protocol must be amended. 
However, there will be periodic reviews of data to assess safet y, tolerabili ty,and PK data. There 
will be sentinel dosing in this protocol ;the initial 2 parti cipants will be rando mized/ dosed
(1ramucirumab :1 placebo) , and subsequent ly (the next day ),the rem aining participants in the 
group will be dosed. The following informat ion belongs in this sect ion:
ï‚·Safety review sare pl anned pri or to dose escalat ion after 2 -week safet y data are 
available .
ï‚·PK data may be reviewed for Groups 1 and 2 if t iming permits.
ï‚·PK data will be reviewed once Group [ADDRESS_842989] been co llected 
(cutoff 2 -week sample collection in Group 3) .
9.6. Data Monitoring Committee (DMC)
Not applicable.
CONFIDENTIAL I4T-MC-JVDT (c)
6010. Supporting Documentation and Operational Considerations
10.1. Appendix 1 : Regulatory, Ethical, and Study Oversight 
Considerations
Regulatory and E thical Considerations
ï‚·This study  will be conducted in accordance wit h the protocol and with the fo llowing:
oconsensus ethical principles derived fro m internat ional guidelines including 
the Decl aration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines
oapplicable Internati onal Council for Harmonisat ion (ICH)Good Clinical 
Practi ce (GCP) Gui delines
oapplicable laws and regulations
ï‚·The protocol, protocol amendments, ICF, I B, and other relevant docum ents ( for 
example , advertisements) must be submitted to an IRB/IEC by  [CONTACT_122641]/IEC before the study  is init iated.
ï‚·Any amendments to the protocol will require IRB/IEC approval before 
implementati on of  change s made to the study  design, except for changes necessary  to 
eliminate an immediate hazard to study  parti cipants.
ï‚·The invest igator will be responsible for the fo llowing:
oproviding wri tten summaries of the status of the study  to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC
onotifying the IRB/IEC of SAEs or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures
oproviding oversight of the conduct of the study  at the site and adherence to 
requi rements of 21 Code of Federal Regulat ions (CFR), ICH gui delines, the 
IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), 
and all other applicable local regulat ions
ï‚·Invest igator sites are compensated for participat ion in the study  as detailed in the 
clinical trial agreement.
Informed Consent Process
ï‚·The invest igator or his/her representative will explain the nature of the study , 
including the risks and benefit s,to the participant or his/her legally author ized 
representative and answer all questi ons regarding the study .
CONFIDENTIAL I4T-MC-JVDT (c)
61ï‚·Parti cipants m ust be inform ed that thei r parti cipat ion is vo luntary. Participants or 
their legally authori zed representative will be required to sign a statement of informed 
consent that mee ts the requi rements of [ADDRESS_842990] (HIPAA) requi rements, where 
applicable, and the I RB/IEC or study center.
ï‚·The m edical  record m ust include a statement that written infor med consent was 
obtained before the participant was enter ed in the study  and the date the wri tten 
consent was obtained. The authori zed person obtaining the informed consent must 
also sign the ICF.
ï‚·Parti cipants m ust be reconsented to the most current versio n of the ICF(s) during th eir 
participat ion in the study.
ï‚·A copy  of the ICF(s) m ust be provi ded to the participant or the participantâ€™s legally  
authori zed representati veand i s kept on file.
Parti cipants who are rescreened are requi red to si gn a new ICF.
Data Protection
ï‚·Parti cipants will be assi gned a unique i dentifier by [CONTACT_456] . Any part icipant 
records ,datasets or tissue samples that are transferred to the sponsor will contain the 
ident ifier only; part icipant names or any  information which would make the 
participant i dentifiable will not be transferred.
ï‚·The parti cipant m ust be inform ed that hi s/her personal  study -related data will  be used 
by [CONTACT_17079] h local data protecti on law . The l evel of disclo sure 
must al so be explained to the participant who will be required to give consent for 
their data to be used as described in the informed consent . 
ï‚·The parti cipant m ust be inform ed that hi s/her m edical  records m ay be examined by 
[CONTACT_17080] y Assurance auditors or other authorized personnel appo inted by  [CONTACT_103], by  [CONTACT_6667]/IEC members, and by [CONTACT_17082].
ï‚·The sponsor has processes in place to ensure data protection, informat ion securit y and 
data integrit y. These processes include appropriate co ntingency plan(s) for 
appropriate and timely  response in the event of a data securit y breach.
Dissemination of Clinical Study Data
Communication of Suspended or Terminated Dosing
If a decisio n is taken to suspend or terminate dosing in the trial due to saf ety findings, this 
decisio n will be communicated by [CONTACT_631717] (for example, by [CONTACT_17084]/or 
email) as soon as possible. It will be a requirement that invest igators respond upon receipt to 
confirm that they  understand the communicat ion and have taken the appropriate action prior to 
further dosing any  parti cipants wi th study  interventi on. Any  invest igator not responding will be 
followed up by  [CONTACT_631718]. If a dose is planned 
imminent ly, the sponsor personnel will immediately, and cont inually, use all efforts to reach 
investigators until contact [CONTACT_17086].
CONFIDENTIAL I4T-MC-JVDT (c)
62Reports
The sponsor will disclose a summary o f study  information, including tabular study results, on 
publicly available websites where required by [CONTACT_317792].
Data 
The sponsor does not proactively share data from Phase 1 clinical trials. Requests for access to 
Phase 1 clinical trial data are evaluated on a case-by-case basis taking into considerat ion the 
abilit y to anonymize the data and the nature of the data collected.
Data Quality Assurance
ï‚·All parti cipant data rel ating to the study  will be recorded on printed or electronic 
CRF sunless transmitted to the sponsor or designee electronically ( for examp le, 
laboratory  data) . The investigator is responsible for verifying that data entries are 
accurate and correct by  [CONTACT_134123].
ï‚·The invest igator must maintain accurate documentation (source data) that supports 
the informat ion entered in the CRF. This might include laboratory  tests, m edical  
records, and clinical notes.
ï‚·The invest igator must permit study -related m onitoring, audi ts, IRB/IEC revi ew, and 
regul atory  agency inspecti ons and provi de di rect a ccess to source data documents.
ï‚·Moni toring details describing strategy  (for example , risk-based init iatives in 
operati ons and qualit y such as Risk Management and Mit igation Strategies and 
Analyt ical Risk -Based Moni toring), m ethods, responsibilit ies,and requi rements, 
including handling of nonco mpliance issues and monitoring techniques are provided 
in the Monitoring Plan.
ï‚·The sponsor or designee is responsible for the data management of this study 
includin g qualit y checking of the data.
ï‚·The sponsor assumes accountabilit y for actions delegated to other individuals ( for 
example , contract research organizat ions).
ï‚·Study  monitors will perform  ongoing source data verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and 
verifiable f rom source docum ents; that the safet y and ri ghts of  parti cipants are being 
protected; and that the study  is being conducted in accordance with the current ly 
approved protocol and any other study  agreem ents, ICH GCP, and all applicable 
regulatory requi remen ts.
ï‚·Records and documents, including signed ICFs, pertaining to the conduct of this 
study  must be retained by  [CONTACT_631719] a longer 
retenti on peri od. No records may be destroy ed during the retention period without the 
written approval  of the sponsor . No records may be transferred to another locat ion or 
party  without wri tten notificat ion to the sponsor .
CONFIDENTIAL I4T-MC-JVDT (c)
63ï‚·In addi tion, the sponsor or its representatives will periodically check a sample of the 
participant data recorded against source documents at the study  site. The study  may 
be audited by [CONTACT_631720]/or regul atory  agencies at any  
time. Invest igators will be given notice before an audi t occurs. 
Data Capture System
The invest igator is responsible for ensuring the accuracy, completeness, legibilit y, and timeliness 
of the data reported to the sponsor . 
An electronic data capture (EDC) system  will be used in this study for the collect ion of CRF 
data. The invest igator maintains a separate source for the data entered by [CONTACT_32864] -provided EDC system. The invest igator is responsible for the 
ident ificat ion of any data to be considered and for the confirmat ion that data reported are 
accurate and complete by  [CONTACT_11003] .
Data collected via the sponsor -provided data capture system (s)will be stored at third party . The 
investigator will have cont inuous access to the data during the study and unt il deco mmissio ning 
of the data capture sy stem (s).Prior to decommissioning, the invest igator will receive an archival 
copy  of pertinent data for retention.
Data m anaged by  a central  vendor, such as laboratory  test data, will be stored electronically in 
the central  vendorâ€™s database system and reports/electronic transfers will be provi ded to the 
investigator for review and retention. Data will subsequent ly be transferred fro m the central  
vendor to the sponsor data warehouse.
Data from co mplaint forms submitted to the sponsor will be encoded and stored in the global 
product complaint management sy stem .
Source Documents
ï‚·Source documents provide evidence for the existence of the participant and 
substant iate the integrity  of the data collected . Source docu ments are filed at the 
investigatorâ€™s site.
ï‚·Data reported on the CRF or entered in the eCRF that are transcribed fro m source 
docum ents m ust be consistent with the source documents or the discrepancies must be 
explained . The invest igator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
ï‚·Definit ion of what constitutes source data can be found in Section10.1.[ADDRESS_842991] been co llected and a study -site closure visi t has been performed.
CONFIDENTIAL I4T-MC-JVDT (c)
64The invest igator may init iate study -site closure at any  time, provi ded there i s reasonable cause 
and sufficient notice is given in advance of the intended terminat ion.
Reasons for the early closure of a study  site by [CONTACT_631721] ,but are 
not limited to:
ï‚·failure of the invest igator to comply wit h the protocol, the requirements of the 
IRB/IEC or local healt h authorit ies, the sponsor â€™s procedures, or GCP guidelines
ï‚·inadequate recrui tment of parti cipan ts by  [CONTACT_17062]
ï‚·discontinuat ion of further study  intervent ion development
If the study  is prem aturely  terminated or suspended, the sponsor shall prompt ly inform  the 
investi gators, the IECs/IRBs, the regulatory  authori ties, and any contract research organi zation(s) 
used in the study  of the reason for terminat ion or suspensio n, as specified by [CONTACT_17096] . The investigator shall prompt ly inform  the participant and shoul d assure 
appropriate participant therapy  and/or foll ow-up.
Publication Policy
In accordance with the sponsorâ€™s publication po licy, the results of this study will be submitted 
for publicat ion by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.
Long- Term Sample Retention
Sample retenti on enables use of new techno logies, response to regul atory  quest ions, and 
investigat ion of variable response that may not be observed unt il later in the development 
oframucirumab .
Sample Type Custodian Retention Period After Last 
Participant Visit
Long -term storage samples Sponsor or Designee 15 years
Biomarkers Sponsor or Designee 15 years
PK Sponsor or Designee 1year 
Genetics/PD Sponsor or Designee 15 years
Immunogenicity Sponsor or Designee 15 years
Abbreviations: PD = pharmacodynamic; PK = pharmacokinetic.
CONFIDENTIAL I4T-MC-JVDT (c)
6510.2. Appendix 2 : Clinical Laboratory Tests
ï‚·The tests detailed belowwill be performed by [CONTACT_12082] .
ï‚·Protocol -specific requirements for inclusio n or exclusio n of participants are detailed 
in Section 5of the protocol .
ï‚·Addit ional serum  or urine pregnancy  tests may  be perform ed, as determined 
necessary  by [CONTACT_631722], to establish the 
absence of pregnancy at any  time during the participant â€™s parti cipat ion in the 
study .
ï‚·Addit ional tests may be performed at any  time during the study  as determined 
necessary  by [CONTACT_317796].
ï‚·Pregnancy testing (Secti on 5.1)
Invest igators must document their review of each laboratory  safety  report.
Laboratory  resul ts that coul d unblind the study  will not be reported to invest igative site or other 
blinded personnel.
CONFIDENTIAL I4T-MC-JVDT (c)
66Safety Laboratory Tests
Hematology Clinical Chemistry
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate 
Mean cell volume Chloride
Mean cell hemoglobin Calcium (ionized/total)
Mean cell hemoglobin concentration Phospho rus/Phosphate 
Leukocytes (WBC) Magnesium
Platelets Glucose (fasting)
Differential WBC (absolute counts) of : Blood urea nitrogen (BUN)
Neutrophils Creatinine
Lymphocy tes Uric acid
Monocytes Total cholesterol
Eosinophils Total protein
Basophils Albumin
Total bilirubin
Coagulation Alkaline phosphatase (ALP)
Prothrombin time (PT or INR) Aspartate aminotransferase (AST)
Partial thromboplastin time (PTT or aPTT) Alanine aminotransferase (ALT)
Gamma -glutamyl transferase (GGT)
Urinalysis
Specific gravity
pH Thyroid-stimulating hormone
Protein Free thy roxine (T4)
Glucose Hepatitis B surface antigen a,b
Ketones Hepatitis C antibody a,b
Bilirubin HIV b
Urobilinogen Urine drug screen c
Blood Breath e thanol testing c
Nitrite FSH
Microscopic examination of sediment d Beta human chorionic gonadotropin
Pregnancy test e
Serum Immunoglobulins
   IgG Hypersensitivity Tests f
   IgM Anti-LY antibodies (immunogenicity)
   IgA LY concentration (PK)
Tryptase g
QuantiFERONÂ® -TB Gold Test or N-methy lhistamine
Tuberculin Skin Test Complements
C3a
C5a
Cytokine Panel
IL-[ADDRESS_842992] h
Abbreviations: aPTT = activated partial thromboplastin time; FSH = follicle -stimulating hormone; HIV = human 
immunodeficiency virus; Ig = immunoglobulin ;IL = interleukin; INR = international normalized ratio; PK = 
pharmacokinetic; PT = prothrombin; PTT = partial thromboplastin time; RBC =red blood cell; WBC = white blood cell.
CONFIDENTIAL I4T-MC-JVDT (c)
67Note : Results of these assays will be validated by [CONTACT_32866] . Additional tests may be performed or 
auto-calculated by [CONTACT_32867] . Some of the above parameters are 
calculated from measured values . Omission of calculated values will not be considered as a protocol violation.
aPerformed at screening only .
bThese tests may be waived if perf ormed within [ADDRESS_842993] results are available for â€œreviewâ€ for 
Hepatitis B and C and HIV.
cUrine drug screen and breath ethanol level will be performed at screening and repeated prior to admission to the clinical 
research unit and at other times indicated in the Schedule of Activities. 
dTest only if dipstick result is abnormal.
eInvestigator -designated/local. Serum pregn ancy test will be conducted at screening only. Urine pregnancy test will be 
conducted at all other time points. A beta human chorionic gonadotropin test may be performed to confirm a result that is 
positive or in the postmenopausal range.
fCentral laborat ory. Additional tests and local laboratory tests may be performed at the discretion of the investigator.
gIf a tryptase sample is obtained more than 2 hours after the event (i.e. within 2 to 12 hours), or is not obtained because more 
than [ADDRESS_842994] la psed since the event, obtain urine for N-methylhistamine (NMH) testing. Note that for tryptase serum 
samples obtained within [ADDRESS_842995] is an in 
vitro cell-based assay that only requires a serum sample. It is a surrogate assay for drug-specific IgE but is not specific fo r 
IgE.
Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sampling (screening, safet y laboratori es, and bioanaly tical assays) during the study . 
PurposeBlood Volume per 
Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a 35.7 1 35.7
Clinical laboratory tests a 12.5 10 125
Coagulation a
(PT or INR ; PTT or aPTT )2.7 1 2.7
Serum immunoglobulins
(IgG, IgM, IgA)3.5 4 14
Thyroid-stimulating hormone 
(including T4)3.5 3 10.5
Pharmacokinetics 2.5 15 37.5
Immunogenicity 10 4 40
Hypersensitivity/Infusion -related 
reaction b24 3 72
Pharmacogenetics 10 1 10
Total 347.4
Total for clinical purposes (rounded up to nearest 10 mL ) 350
Abbreviations: Ig = immunoglobulin; INR = international normalized ratio; PT = prothrombin; PTT = partial thromboplastin 
time.
aAdditional samples may be drawn if needed for safety purposes.
bOnly in the event of drug hypersensitivity reactions (immediate or nonimmediate).
CONFIDENTIAL I4T-MC-JVDT (c)
6810.3. Appendix 3 : Adverse Events : Definitions and Procedures for 
Recording, Evaluating, Follow -Up, and Reporting
Definition of AE
AE Definition
ï‚·An AE is any  untoward m edical  occurrence in a pati ent or clinical study  parti cipant, 
temporally  associ ated wi th the use of study  intervent ion, whether or not considered 
related to the study  intervent ion.
ï‚·NOTE : An AE can therefore be any unfavorable and unintended si gn (including an 
abnorm al laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associ ated wi th the use of study  intervent ion.
Events Meeting the AE D efinition
ï‚·Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments ( for example , ECG, radi ological scans, vi tal signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the invest igator (that is, not rel ated 
to progressi on of  underlying disease).
ï‚·Exacerbat ion of a chronic or intermittent preexisting condit ion,including eit her an 
increase in frequency and/or intensit y of the condi tion.
ï‚·New condi tions detected or di agnosed after study  intervent ion administration even 
though i t may have been present before the start of the study .
ï‚·Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
ï‚·Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
interventi on or a concomitant medicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose should be reported regardless of sequelae.
ï‚·The signs, symptoms, a nd/or clinical sequelae result ing from lack of efficacy will be 
reported as AE or SAE if they  fulfillthe defini tion of  an AE or SAE . Also, â€œ lack o f 
efficacy â€ or â€œ failure of expected pharmaco logical acti onâ€also consti tutes an AE or SAE.
Events NOT Meeting the AE D efinition
ï‚·Any clinically  significant abnormal  laboratory  findings or other abnormal safet y 
assessments which are associated with underlying disease, unless judged by [CONTACT_11009]â€™s condi tion.
ï‚·The disease/disorder being studied or expected progressio n, signs, or symptom s of the 
disease/disorder being studied, unless more severe than expected for the participantâ€™s 
condi tion.
CONFIDENTIAL I4T-MC-JVDT (c)
69ï‚·Medical or surgical procedure ( for example, endoscopy , append ectomy ): the condi tion 
that leads to the procedure is the AE.
ï‚·Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admissio n to a hospi[INVESTIGATOR_307]).
ï‚·Anticipated day -to-day fluctuations of preexist ingdisease(s) or condi tion(s) present or 
detected at the start of the study  that do not worsen.
Definition of SAE
If an event is not an AE per the definit ion above, then it cannot be an SAE even if serious 
condi tions are m et (for example, hospi [INVESTIGATOR_17045]/symptom s of the di sease under study , 
death due to progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term â€˜life-threatening â€™in the definit ion of â€˜serious â€™refers to an event in which the 
participant was at ri sk of death at the time o f the event . It does not refer to an event, which 
hypotheti cally  might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
ï‚·In general, hospi[INVESTIGATOR_631697]/or treatment that would not have been appropriate in the physicianâ€™s 
office or outpatient setting . Com plicat ions that occur du ring hospi[INVESTIGATOR_41365]. If a 
complicat ion prol ongs hospi [INVESTIGATOR_631698], the event i s 
serious. When in doubt as to whether â€œhospi[INVESTIGATOR_3094]â€ occurred or was necessary, the AE 
shoul d be considered serious.
ï‚·Hospi [INVESTIGATOR_10912] a preexist ingcondi tion that di d not worsen from 
baseline is not considered an AE.
d.Results in persistent disability/incapacity
ï‚·The term disabilit y means a substant ial disrupt ion of a personâ€™s abilit y to conduct norm al 
life f unctions.
ï‚·This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated headache, nausea, vomit ing, di arrhea, influenza, and 
accidental  traum a (for example, sprained ankle) which may  interfere wi th orprevent 
everyday life functions but do not constitute a substantial disrupt ion.
e.Is a congenital anomaly/birth defect
f.Other situations:
ï‚·Medical or scient ific judgment should be exercised in deciding whether SAE reporting is 
CONFIDENTIAL I4T-MC-JVDT (c)
70appropriate in other situation s such as important medical events that may  not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_631699] e definit ion. These events should usually be considered 
serious.
ï‚·Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room  or at hom e for allergic bronchospasm, blood dy scrasias or convulsio ns 
that do not resul t in hospi[INVESTIGATOR_3094], or development of drug dependency or drug abuse.
Recording and Follow -Up of AE sand/or SAE s
AE and SAE Recording
ï‚·When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (for example, hospi [INVESTIGATOR_1088], l aboratory  reports, and di agnostics 
reports) rel ated to the event.
ï‚·The invest igator will then record all relevant AE/SAE informat ion on the CRF.
ï‚·It is notacceptable for the invest igator to send photocopi[INVESTIGATOR_10914]â€™s med ical 
records to the sponsor or designee in lieu of completion of the AE/SAE CRF page.
ï‚·There m ay be instances when copi[INVESTIGATOR_242897] . In thi s case, all part icipant identifiers, with the exce ption of  the 
participant number, will be redacted on the copi[INVESTIGATOR_17051] n to the sponsor or designee .
ï‚·The invest igator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical informa tion. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The invest igator will make an assessment of intensity for each AE and SAE reported duri ng the 
study  and assi gn it to 1 of the following categories : 
ï‚·Mild : An event that is easily tolerated by [CONTACT_2299], causing minimal disco mfort and 
not interfering wit h every day act ivities.
ï‚·Moderate: An event that causes sufficient discomfort and interferes wit h norm al everyday 
activit ies.
ï‚·Severe : An event that prevents normal everyday activit ies. An AE that is assessed as 
severe should not be confused with a nSAE . Severe is a category ut ilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.
ï‚·An event is defined as â€˜seriousâ€™ when it meets at least 1 of the predefined outcomes 
described in the definit ion of an SAE, NOT when it is rated as severe.
ï‚·The invest igator will u se CTCAE versio n 5.0 (NCI 2018) to assign AE severit y grades.
CONFIDENTIAL I4T-MC-JVDT (c)
71Assessment of Causality
ï‚·The invest igator is obligated to assess the relationship between study intervent ion and 
each occurrence of each AE/SAE.
ï‚·A â€œreasonable possibilit yâ€ of a relationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relat ionship,cannot be ruled out.
ï‚·The invest igator will use clinical judgment to determine the relat ionship.
ï‚·Alternat ive causes, such as underlying disease(s), concomitant therapy , and other ri sk 
factors, as well as the temporal relationship of the event to study  intervent ion 
administration ,will be considered and invest igated.
ï‚·The invest igator will also consult the IB and/or Product Information, for marketed 
products, in his/her assessment.
ï‚·For each AE/SAE, the invest igator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causalit y.
ï‚·There m ay be si tuations in which an SAE has occurred and the inv estigator has minimal 
inform ation to include in the init ial report to the sponsor or designee . However, it is very 
important that the invest igator always make an assessment of causalit y for every  event 
before the init ial transmissio n of the SAE data to thesponsor or desi gnee .
ï‚·The invest igator may change his/her opi[INVESTIGATOR_3078] n of causalit y in light of fo llow-up 
inform ation and send a nSAE follow -up report wi th the updated causalit y assessment.
ï‚·The causalit y assessment is one of the cri teria used when determining r egulatory  
reporting requirements.
Follow -Up of AEs and SAEs
ï‚·The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluat ions as medically indicated or as requested by [CONTACT_41443]/or causalit y of the AE or SAE as fully as possible . 
This m ay include addit ional laboratory  tests or investigations, histopathological 
examinat ions, or consultation with other health care professio nals.
ï‚·If a participant dies dur ing participation in the study or during a recognized fo llow-up 
period,the invest igator will provide the sponsor or desi gnee with a copy  of any 
post mortem findi ngs,including histopathology .
ï‚·New or updated informat ion will be recorded on the originally completed CRF.
ï‚·The invest igator will submit any updated SAE data to the sponsor or designee within 
24hours of receipt of the information.
CONFIDENTIAL I4T-MC-JVDT (c)
72
Reporting SAEs
SAE Reporting
ï‚·The invest igator or site must alert Lilly CRP/CP, or its designee, of  any SAE as soon as 
practi cally  possible .
ï‚·Addit ionally, the invest igator or site must alert Lilly Global Pat ient Safet y, or its 
designee, of any SAE within 24 hours of investigator awareness of the event via a 
sponsor -approved method. If alerts are issued via telephone, th ey are to be immediately 
followed wi th official  notificat ion on study -specific SAE forms. This 24 -hour 
notification requirement refers to the init ial SAE informat ion and all fo llow-up SAE 
inform ation.
ï‚·Facsimile transmissio n of the SAE Form is the preferr ed m ethod to transmit this 
inform ation to the sponsor or designee .
ï‚·In rare circumstances and in the absence of facsimile equipment, notificat ion by 
[CONTACT_394115] h a copy  of the SAE Form sent by  [CONTACT_208895] m ail or couri er 
service , or em ail.
ï‚·Initial notificati on via telephone does not replace the need for the invest igator to 
complete and sign the SAE Form  within the designated reporting time frames.
ï‚·Contacts for SAE reporting can be found in the SAE Form.
Sponsor Surveillance Process for Dose Escalation or Group Expansion
The sponsor has systemat ic and robust internal processes in place that ensure safet y surveillance 
of devel opment com pounds in line wit h Food and Drug Administrati onâ€™s (FDAâ€™s )expectati ons 
for safet y assessment committees (SAC s) (FDA 2012, 2015, 2018a, 2018b) . This includes 
processes with clearly described ro les and responsibilit ies that are owned by [CONTACT_456] â€™s 
Global Patient Safet y organi zation. These processes are designed to monitor the evo lving safet y 
profile ( that is,review of cumulat ive SAEs, other important safet y informat ion) by [CONTACT_631723] -functional team sin a t imely manner at predefined intervals or on an ad hoc basis. In 
addition, a dedi cated process may be used to perf orm unblinded co mpar isons of event rates for 
SAEs as necessary. 
This system ensures that the accumulat ing safet y data deri ved from individual and mult iple trials 
across a development program is reviewed on a regular basis and that important new safet y 
information,such as the need for protocol modification or other relevant safet y-related m aterial ,
is ident ified and co mmunicated to regulators and investigators appropriately and in a t imely 
fashio n. An internal review of aggregate safet y data occurs on at l east a quarterly  basis or m ore 
frequently, as appropriate. Any serious adverse reacti ons ( SAR s) are reported within the required 
timeline for expedited reporting.
In addi tion to annual periodic safet y updates and to further inform invest igators, a line lis ting 
report of suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) is created and distributed to 
investigators on a biannual (twice y early) basis. Any  significant potenti al risk/safety  concerns 
that are being monitored , as well as any results being rep orted i n other peri odic reports for the 
CONFIDENTIAL I4T-MC-JVDT (c)
73compound, SAC decisio ns, and other significant safet y data (for example, nonclinical and 
clinical findings, removal of SARs) are included in the report.
CONFIDENTIAL I4T-MC-JVDT (c)
7410.4. Appendix 4 : Contraceptive Guidance and Collection of Pregnancy
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A wo man is considered fertile fo llowing menarche and unt il beco ming postmenopausal unless 
perm anent ly sterile (see below).
If fertilit y is unclear ( for example , amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study  intervent ion, addi tional evaluat ion shoul d be 
considered.
Women in the fo llowing categori es are not considered WOCBP
1. P remenarchal
2. P remenopausal  female wi th 1 of the f ollowing:
ï‚·docum ented hysterectomy
ï‚·docum ented bilateral  oophorectomy
ï‚·docum ented tubal  ligation
For individuals wit h perm anent infert ility due to an alternate medical cause other than the above, 
(for example , mullerian agenesis, androgen insensitivit y), investi gator di scret ion shoul d be 
applied to determining study  entry .
Note : Documentation can come fro m the site personnelâ€™s : review of the participantâ€™s medical 
records, medical examinat ion, medical history  interview , or pri or docum ented medical history  at 
the site, and may be docum ented in the m
edical history .
3.Postmenopausal  female is defined as women wit h:
ï‚·at least 6 weeks postsurgical bilateral oophorectomy  with-or-without hy sterectomy , 
confirmed by [CONTACT_31083] /medical records
OR
ï‚·with spontaneous amenorrhea for at least 12 months, not induced by a medical condit ion 
such as anorexia nervosa and not taking medications during the amenorrhea ( for example,
oral contraceptives, hormones, gonadotropin releasing hormone, ant i-estrogens, sel ective 
estrogen receptor modulator s [SERMs ], or chem otherapy that induced the amenorrhea ).
AND
ï‚·if â‰¤ age 5 5, has a follicle -stimulat ing hormone of â‰¥40 m IU/mL 
Contraception Guidance:
See Secti on 5.1.
Collection of Pregnancy Information
Male participants wi th partners who become pregnant
ï‚·The invest igator will attempt to collect pregnancy informat ion on any male 
participantâ€™s female partner who beco mes pregnant while the male participant is in 
this study . This applies only to male part icipants who receive study  intervent ion.
CONFIDENTIAL I4T-MC-JVDT (c)
75ï‚·After obtaining the necessary  signed informed consent from the pregnant female 
partner direct ly, the invest igator will record pregnancy informat ion on the appropriate 
form and submi t it to the sponsor within 24 hours of learning of the partnerâ€™s 
pregnancy .The female partner will also be fo llowed to determine the outcome of the 
pregnancy . Inform ation on the status of the mother and child will be forwarded to the 
sponsor . Generally, the fo llow-up will be no longer than 6 to 8 weeks fo llowing the 
estimated de livery date . Any terminat ion of the pregnancy will be reported regardless 
of fetal status (presence or absence of ano malies) or indicat ion for the procedure . 
Female participants who become pregnant
ï‚·The invest igator will co llect pregnancy information on an y female participant who 
beco mes pregnant while participat ing in this study . The init ial informat ion will be 
recorded on the appropriate form and submitted to the sponsor within 24 hours of 
learning of a participant â€™s pregnancy . 
ï‚·The parti cipant will be fo llowed to determine the outcome of the pregnancy . The 
investigator will co llect fo llow-up inform ation on the participant and the neonate and 
the informat ion will be forwarded to the sponsor . Generally, fo llow-up will not be 
requi red for longer than 6 to 8 weeks beyo nd the estimated delivery date . Any 
termination o f pregnancy will be reported, regardless of fetal status (presence or 
absence of ano malies) or indicat ion for the procedure.
ï‚·While pregnancy  itself is not considered to be an AE or SAE, any  pregnan cy 
complicat ion or el ective terminat ion of a pregnancy  for medical  reasons will be 
reported as an AE or SAE . 
ï‚·A spontaneous abortion (occurring at <2 0weeks gestational age) or still birth 
(occurring at >20 weeks gestational age) is always considered to be an SAE and will 
be reported as such . 
ï‚·Any poststudy  pregnancy -related SAE considered reasonably  related to the study  
intervent ion by [CONTACT_41444]
8.3.[ADDRESS_842996] igator is not obligated to actively seek this informat ion in 
former study  parti cipants, he or she may  learn of an SAE through spontaneous 
reporting.
ï‚·Any female part icipant wh o becom es pregnant while participat ing in the study  will 
discontinue study  interventi on or be wi thdrawn from the study .
CONFIDENTIAL I4T-MC-JVDT (c)
7610.5. Appendix 5: Genetics
Use/Analysis of DNA
ï‚·Genet ic variat ion may impact a participantâ€™s response to study  intervent ion, 
suscept ibilit y to, and severit y and progression o f disease. Variable response to study  
intervent ion may be due to genet ic determinants that impact drug absorption, 
distribut ion, metabo lism, and excretion , mechanism o f action of the drug, disease 
etiology, and/or mo lecula r subt ype of the disease being treated. Therefore, where 
local regulati ons and IRB s/IEC sallow, a blood sample will be collected for DNA 
analysis fro m consent ing participants.
ï‚·DNA samples will be used for research related to study  intervent ionor cancer and 
related diseases. They may  also be used to develop tests/assays including diagnostic 
tests related to study  intervent ion and/or intervent ions of this drug class and cancer . 
Genet ic research may consist of the analysis o f 1 or more candidate genes or the 
analysis of genet ic markers throughout the geno me or analysis o f the ent ire geno me
(as appropriate).
ï‚·Addit ionalanalyses m ay be conducted if it is hypothesized that this may  help further 
understand the clinical data.
ï‚·The samp les may be analyzed as part of a mult istudy  assessment of genetic factors 
involved in the response to study  intervent ionor study  intervent ions of thi s class to 
understand study  disease or related condit ions.
ï‚·The sponsor will store the DNA samples in a sec ure storage space with adequate 
measures to protect confident iality.
ï‚·The samples will be retained while research on study  intervent ion or study  
intervent ions of this class or indicat ioncontinues but no l onger than 15years or other 
time period as per l ocal requi rements.
CONFIDENTIAL I4T-MC-JVDT (c)
7710.6. Appendix 6: Pharmacokinetic Profile Simulation (I ntravenous versus 
Subcutaneous )
The PK profile for IV (10 mg/kg Q2W) and SC administration of ramucirumab (Left panel: 
1400- mg SC loading dose on Day 1 fo llowed by [CONTACT_631724] 700 mg; Right panel: 1400- mg SC 
loading dose on Day  1 followed by  [CONTACT_27656]-weekly [ BIW ]SC 350 mg) is shown in the figure 
below.
Abbreviations: BIW = twice weekly; IV = intravenous; LD = loading dose; Q2W = every 2 weeks; QW =once 
weekly; Ram =ramucirumab; SC = subcutaneous.

CONFIDENTIAL I4T-MC-JVDT (c)
78Model -Simulated Ramucirumab AUC, Average, Trough, and Peak Concentrations 
Following Intravenous (10 mg/kg Q2W) and Subcutaneous Administration of 
Ramucirumab ( 1400- mg SC loading dose on Day 1 follow ed by [CONTACT_631725] [QW] SC 
700mg or twic e weekly [BIW] SC 350 mg)
10 mg/kg Q2W IV 
RELAYSC LD 1400 mg + SC MD 
350 mg BIWSC LD 1400 mg + SC 
MD 700 mg QWRATIO
RATIO
SC 350 / 
IV 10SC 700 / 
IV 10
Median5th-95th
percentile Median5th-95th
percentile Median5th-95th
percentile Median Median
Week 1&2 PK parameters
AUC1 mg.h/mL 18.1 13.2 -25.4 16.3 10.6 -25.1 14.8 9.61 -22.9 0.90 0.82
AUC2 mg.h/mL 26.2 18.2 -38.2 39.2 24.8 -61.5 35.8 22.6 -56.2 1.50 1.37
CavÂµg/mL 
Week1108 79-151 97 63-149 88.1 57-136 0.9 0.82
CavÂµg/mL 
Week248 30-76 136 85-217 125 77-198 2.83 2.59
CmaxÂµg/mL 206 153-285 141 87-227 134 83-212 0.68 0.65
Ctrough Âµg/mL 35 16-58 133 80-218 112 66-184 3.86 3.25
Steady state SS PK parameters
AUC ssmg.h/mL 48.0 30-75 59 33-102 59 34-102 1.23 1.23
CavÂµg/mL 143 90-223 176 99.4-305 176 100-305 1.23 1.23
CmaxÂµg/mL 285 200-412 178 100-308 186 106-318 0.62 0.65
Ctrough Âµg/mL 77 38-138 170 96-296 157 86-278 2.21 2.04
Ratio C trough
SS/WEEK1&22.23 1.28 1.40
Caverage to trough 
WEEK21.38 1.02 1.12
Peak to trough at 
SS3.7 1.05 1.18
Abbreviations :AUC ss= area under the curve at steady state over 2 weeks; AUC1 = area under the curve during the 
first week of treatment; AUC2 =area under the curve during the first 2 weeks of treatment ;BIW =twice weekly; 
Cav= average concentration ; Cmax= maximum concentration ; Ctrough =trough min concentration at the end of the 
dosing interval ; IV = intravenous; LD =loading dose; MD = maintenance dose; PK=pharmacokinetic; 
SC=subcutaneous; SS = steady state; Q2W = ever y 2 weeks; QW = once weekly .
CONFIDENTIAL I4T-MC-JVDT (c)
79Model -Simulated Ramucirumab AUC, Average, Trough, and Peak Concentrations 
Following Intravenous (13 mg/kg QW) and Subcutaneous Administration of Ramucirumab 
(1400- mg SC loading dose on Day 1 followed by [CONTACT_631725] [QW] SC 7 00mg or twice 
weekly [BIW] SC 350 mg)
13 mg/kg IV QW 
MTDSC LD 1400 mg + SC MD 
350 mg BIWSC LD 1400 mg + SC MD 
700 mg QWRATIO -
MOSRATIO -
MOS
IV 13 
mg/kg
QW/SC 70
0IV 13 
mg/kg
QW/ SC35
0
Median5th-95th
percentile Median5th-95th
percentile Median5th-95th
percentile Median Median
Week 1&2 PK parameters
AUC1 
mg.h/mL23.5 17.1 -33.1 16.3 10.6 -25.1 14.8 9.61 -22.9 1.6 1.4
AUC2 
mg.h/mL58 41.2 â€“ 83 39.2 24.8 -61.5 35.8 22.6 -56.2 1.6 1.5
CavÂµg/mL 
Week1140 101-197 97 63-149 88 57-136 1.6 1.5
CavÂµg/mL 
Week2205 143-297 136 85-217 125 77-198 1.6 1.5
Cmax
Âµg/mL353 259-495 141 87-227 134 83-212 2.6 2.5
Ctrough
Âµg/mL135 82-207 133 80-218 112 66-184 1.2 1.0
Steady state SS PK parameters
AUC ,ss
mg.h/mL125 78-194 59 33-102 59 34-102 2.11 2.11
CavÂµg/mL 371 233-578 176 99.4-305 176 100-305 2.11 2.11
Cmax
Âµg/mL540 366-804 178 100-308 186 106-318 2.9 3.03
Ctrough
Âµg/mL270 153-433 170 96-296 157 86-278 1.72 1.59
Abbreviations :AUC ss= area under the curve at steady state over 2 weeks; AUC1 = area under the curve during the 
first week of treatment; AUC2 = area under the curve during the first 2 weeks of treatme nt; BIW =twice weekly; 
Cav= average concentration; C max= maximum concent ration; C trough =trough min concentration at the end of the 
dosing interval; IV = intravenous; LD =loading dose; MD = maintenance dose; PK =pharmacokinetic; 
SC=subcutaneous; SS = steady state; QW = once weekly. 
CONFIDENTIAL I4T-MC-JVDT (c)
8010.7. Appendix 7: Abbreviations
Term Definition
ADA antidrug antibody
AE adverse event
AESI adverse event of special interest
ATE arterial thromboembolic event
AUC area under the concentration versus time curve
BIW twice weekly
blinding/masking A single -blind study is one in which the investigator and/or his staff are aware of the 
treatment but the participant is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the participant are not.
A dou ble-blind study is one in which neither the participant nor any of the investigator 
or sponsor staff who are involved in the treatment or clinical evaluation of the 
participants are aware of the treatment received.
BMI body mass index
Cav average drug concentration during the dosing interval for a single dose
Cmax maximum drug concentration
Ctrough minimal/predose concentration before the next dose
CFR Code of Federal Regulations 
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or dru g delivery system.
compliance Adherence to all study -related, GCP, and applicable regulatory requirements.
COVID -[ADDRESS_842997]
CRC colorectal cancer
CRF/eCRF case report form/electronic case report form
CRP clinical research physician: Individual responsible for the medical conduct of the study. 
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
CONFIDENTIAL I4T-MC-JVDT (c)
81CRU clinical research uni t
CSR clinical study report
CTCAE Common Terminology Criteria for Adverse Events
DMC data monitoring committee
DNA deoxyribonucleic acid
ECG electrocardiogram
EDC electronic data capture
enroll The act of assigning a participant to a treatment. Participants who are enrolled in the 
study are those who have been assigned to a treatment.
enter Participants entered into a study are those who sign the informed consent form directly 
or through their legally acceptable representatives.
FDA Food and Drug Administration
FSH follicle -stimulating hormone
GCP Good Clinical Practice
GEJ gastroesophageal junction
GI gastrointestinal
HCC hepatocellular carcinoma
HIPAA Health Insurance Portability and Accountability Act
HIV human immunodeficiency virus 
IB Investigatorâ€™s Brochure
ICF informed consent form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
informed consent A process by [CONTACT_9444] a participant voluntarily confirms his or her willingne ss to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participantâ€™s decision to participate. Informed consent is 
documented by [CONTACT_3553] a written, signed and dated informed consent form.
IP investigational product
IRB Institutio nal Review Board
IRR infusion -related reaction
CONFIDENTIAL I4T-MC-JVDT (c)
82ISP injection site pain
ISR injection site reaction
IV intravenous(ly)
mAb monoclonal antibody
MedDRA Medical Dictionary for Regulatory Activities
NIMP noninvestigational medicinal product
NOAEL no-observed -adverse -effect level
NSCLC non-small cell lung cancer
participant equivalent to CDISC term â€œsubjectâ€: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_631700] a control
PD pharmacodynamic(s)
PK pharmacokinetic(s)
PRES posterior reversible encephalopathy syndrome
Q2W every 2 weeks
QTc corrected QT interval
QW once weekly
SAC safety assessment committee
SAE serious adverse event
SAP statistical analysis plan
SAR serious adverse reaction
SC subcutaneous(ly)
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SERM selective estrogen receptor modulator
SoA Schedule of Activities
S[LOCATION_003]R suspected unexpected serious adverse reaction
t1/2 apparent terminal elimination half -life
tmax time of maximum concentration
CONFIDENTIAL I4T-MC-JVDT (c)
83TE ADA treatment -emergent antidrug antibody
TE ADA+ treatment -emergent antidrug antibody positive
TEAE treatment -emergent adverse event
ULN upper limit of normal
VAS visual analog scale
VEGF vascular endothelial growth factor
VTE venous thromboembolic event
WOCBP woman/women of childbearing potential
CONFIDENTIAL I4T-MC-JVDT (c)
8410.8. Appe ndix 8 : Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents (TOC).
Amendment (b): 14 July 2020
Overall Rationale for the Amendment:
This amendment addresses feedback from the Unit ed States Food and Drug Administration 
(FDA) .
Section # and 
NameDescription of Change Brief Rationale
1.[ADDRESS_842998] current 
version of MedDRA will be used to 
report AEs and that CTCAE version 
5.0 will be used to assign AE 
severity grades . Indicated that all 
relevant hematology and chemistry 
laboratory values will be graded 
according to CTCAE version 5.0. To address FDA feedback
10.3.3 Recording 
and Follow -Up of 
AEs and/or SAEsIndicated that the investigator will 
use CTCA E version 5.[ADDRESS_842999] not been 
summarized
Abbreviations: AE = adverse event; CTCAE = C ommon Terminology Criteria for Adverse Events ; FDA = United 
States Food and Drug Administration ; MedDRA = Medical Dictionary for Regulatory Activities ; SAE = serious 
adverse event .
CONFIDENTIAL I4T-MC-JVDT (c)
85Amendment (a): 26 June 2020
Overall Rationale for the Amendment:
Due to the COVID -19â€“related increased risks , extending the participantâ€™s inpat ient visits atthe 
clinical research uni
t woul d reduce the exposure and risks.
Section # and Name [CONTACT_23688]
1.1 Synopsis Modified the enro llment ratio to 
10 participants 
(7ramucirumab: 3placebo per 
group) to complete at least 
8participantsTo capture that [ADDRESS_843000] ions, 
changed outpatient visits for Days6, 7, 
and 8 to i npatient vi sits
1.2 Schema Modified schema to include 
7ramucirumab:3 placebo 
participants per group instead of 
6ramucirumab: 2placebo 
participants per groupTo reflect the change in enro llment 
ratio and cl arify that Group 6 will be 
rando mized
1.3 Schedule of 
ActivitiesChanged outpatient visits for
Days 6, 7, and 8 to inpat ient visitsTo minimize the p rocedures for 
check -ins/check -outs due to 
COVID -19
1.3 Schedule of 
ActivitiesIndicated that breath ethanol 
testing will be performedTo cl arify that breath testing will be 
done for al coho l
CONFIDENTIAL I4T-MC-JVDT (c)
86Section # and Name [CONTACT_23688]
1.[ADDRESS_843001] ions, 
changed outpatient visits for Days6, 7, 
and 8 to i npatient vi sits
2.1 Study  
RationaleModified the enro llment ratio to 
10 participants 
(7ramucirumab: 3placebo per 
group) to complete at least 
8participants To capture t hat 10 participants per 
group will be enro lled
4.1 Overall Design Modified the enro llment ratio to 
10 participants 
(7ramucirumab: 3placebo per 
group) to complete at least 
8participants To capture that [ADDRESS_843002] ions, 
changed outpatient visits for Days6, 7, 
and 8 to i npatient vi sits
5.1 Incl usion 
CriteriaUnder inclusio n criterion [7a], 
added wi th spermicideTo add cl arity that cervi cal sponges 
will be used wi th spermicide
5.1 Incl usion 
CriteriaUnder inclusio n criterion [7b], 
removed regardl ess of 
childbearing potentialTo rem ove unnecessary  language 
because females must be of 
nonchildbearing potential
6.1 Study  
Intervention(s) 
AdministeredUnder the placebo for IV column, 
removed reference to SC inject ion 
(Groups 1, 2, 4, 5) and SC 
infusio n with a pum p (Group 6)To rem ove duplicate informat ion that 
was inadvertently populated under the 
placebo for IV column. The placebo 
for SC is captured under the pl acebo 
for SC col umn. 
CONFIDENTIAL I4T-MC-JVDT (c)
87Section # and Name [CONTACT_23688]
6.3 Measures to 
Minimize Bias: 
Randomization 
and BlindingModified the enro llment ratio to 
10 participants 
(7ramucirumab: 3placebo per 
group )to complete at least 
8participants To capture that 10 participants per 
group will be enr olled
6.3 Measures to 
Minimize Bias: 
Randomization 
and BlindingRevised ratio for randomizat ion 
to 7:3 from 3:1To capture that 10 participants per 
group will be enro lled
9.2 Sam ple Si ze 
Determinat ionClarified that participants will be 
rando mly assigned (10per 
group /dose level; 
7ramucirumab:3 placebo) to 
obtain at least 8 evaluable 
participants per group 
(6ramucirumab: 2placebo )To capture that [ADDRESS_843003] not been 
summarized
Abbreviations: COVID -19=coronavirus disease 2019 ; CRU =clinical research unit; IV =intravenous.
CONFIDENTIAL I4T-MC-JVDT (c)
8811. References
[FDA] [LOCATION_002] Food and Drug Administration. Expansio n Cohorts: Use in First -In-Human 
Clinical Trials to Expedite Development of Onco logy Drugs and Bio logics. Draft Guidance. 
Available at: https://www.fda.gov/media/115172/download. July 2018 (2018a). Accessed 
February  20, 2020. 
[FDA] [LOCATION_002] Food and Drug Administration. Master Protocols: Efficient Clinical Trial 
Design Strategies to Expedite Development of Oncology  Drugs and Bio logics. Draft 
Guidance. Available at: https://www.fda.gov/media/120 721/downl oad. August 2018 (2018b). 
Accessed February  20, 2020.
[FDA] [LOCATION_002] Food and Drug Administration. Safety Assessment for IND Safet y 
Reporting . Draf t Gui dance. Available at: https://www.fda.gov/media/[ZIP_CODE]/download. 
December 2015. Accessed Feb ruary  20, 2020.
[FDA] [LOCATION_002] Food and Drug Administration. Saf ety Reporting Requirements for INDs 
and BA/BE Studies . Gui dance. Available at: https://www.fda.gov/media/[ZIP_CODE]/download. 
December 2012. Accessed February  20, 2020.
[NCI] National Cancer Institute. Comm on termino logy criteria for adverse events (CTCAE)
v5.0. Available at:
https://ctep.cancer.gov/protocolDevelopment/electronic_applicat ions/ctc.ht m. Published 
05January 2018. Accessed July 07, 2020 .
Viola M, Sequei ra J, Sei Ã§a R, et al. Subcu taneous delivery  of monocl onal antibodies: how do we 
get there? J Control Release . 2018;286:301 -314.
https://doi .org/10.1016/j .jconrel .2018.08.001
Williamson A, Hoggart B. Pain: a review o f three commo nly used pain rat ing scales. J Clin 
Nurs . 2005;14(7):79 8-804. https://doi.org/10.1111/j.1365 -2702.2005.[ZIP_CODE].x
L e o  D o c u m e n t  I D  =  3 0 1 2 0 5 1 e - d c e 4 - 4 5 c 2 - b 0 d 3 - c 0 f 9 1 b 6 d 3 c e 2 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 1 - O c t - 2 0 2 0  1 2 : 1 8 : 5 7  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 1 - O c t - 2 0 2 0  1 4 : 2 1 : 2 8  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 